Structural and functional studies of the Apical Sodium Dependent Bile Acid Transporter by Sekiguchi, Yusuke
	   1	  
	 
Structural and functional studies of the 
Apical Sodium Dependent Bile Acid 
Transporter 
 
 
Yusuke Sekiguchi 
 
 
 
Division of molecular biosciences 
Imperial College London 
 
 
 
Thesis submitted for the degree of Doctor of Philosophy 
2014 
	   2	  
Abstract 
The apical sodium dependent transporter (ASBT) is responsible for the uptake 
of bile acids from the apical membrane of the ileum cell. Loss of function mutations 
of ASBT relate to several diseases, such as Crohn’s disease and Primary Bile Acid 
Malabsorption (PBAM). It is also a target for drugs aimed at lowering cholesterol. 
The X-ray crystal structure of a bacterial homologue of ASBT, ASBTNM, was 
previously solved at 2.2Å. In order to understand mechanism of ASBT transport in 
more detail, further structural and functional information are required. In this thesis, a 
proteoliposome transport assay was performed for various mutations of residues in the 
sodium and substrate binding sites. ASBTNM has two sodium binding sites and the 
residues involved in the sites are functionally important. Both E260A and Q77A 
showed significantly lower transport activities compared to wild type at 40% and 60% 
respectively. E260 binds to one sodium ion and Q77 the other. The X-ray crystal 
structures of these two ASBTNM mutants were solved at 2.9 Å and 3.2 Å respectively. 
These mutant structures revealed that no large scale conformational changes from the 
wild type were observed though the mutations clearly affected sodium ion binding. 
These structural and functional data suggest that both two sodium ions are important 
for the transport activity of ASBTNM. However even without sodium ions in the 
binding sites, the protein can take the same conformation as the wild type structure. 
The data presented in this thesis, together with a comparison with the results from 
another bile acid transporter that was recently solved, and a homology model of 
human ASBT, provide insight into the transport mechanism of ASBT. 
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1.1. Membrane transport mechanism 
Cell membranes are essential for life as the compartmentalization between the 
inside and outside of the cell or organelle. They also have important roles that include 
maintaining the electrical potential, the organization and regulation of enzyme activity 
and signal transduction. Cell membranes are composed of a lipid bilayer. The polar 
head group of the lipid faces the surface on both sides of the membrane and the 
hydrophobic tail points into the interior. Membrane proteins, embedded in cell 
membranes, constitute one third of human proteins and have a wide range of 
important roles as cellular machinery systems (Wallin and von Heijne 1998). From 
the way they interact with the cell membrane, membrane proteins can be classified 
into several categories, peripheral membrane proteins that associate at the surface of 
the cell membrane, lipid anchored proteins that bind covalently to the fatty acid or 
lipids of the cell membrane and integral membrane proteins. Most membrane proteins 
are categorized as integral proteins that have at least one trans-membrane (TM) 
segment formed by α-helices (helical bundles) or, less frequently, by β-barrel 
components.  
Cell membranes prevent permeation of various polar molecules, such as ions, 
sugars, amino acids, nucleotides and drugs. Membrane transporters, forming the 
second largest family of membrane proteins, are essential for cells as transporting 
gates between the outside and inside of cells for various materials. Transporters help 
to maintain homeostasis of ion/solute gradients across cell membranes and regulate 
signal transfer through calcium ions or neurotransmitters. To move small water-
soluble molecules across membranes, cell membranes contain a wide variety of 
transporters. Each transporter has a specific role by recognizing a particular ion/solute 
in the kidney, intestine, brain or other cell type. They are categorised into two classes 
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by the type of source energy for its transport mechanism, passive and active 
transporter.  
The passive transporters that are involved in facilitated diffusion across cell 
membrane, such as channels and pores, consume only thermal energy as a driving 
force for their transport.  They normally transport solute depending on the direction of 
the solute concentration from the higher side to the lower side. The transfer of specific 
ions by channels occurs as an electron-diffusion through a water filled pore, in which 
remarkably rapid flux as high as 108 ions per second. (Alberts 2010) The pores of 
these channels are usually strictly regulated and allow their substrate to pass through 
only when they are temporarily opened as a response to the signal from the cell 
environment including a change in the membrane potential.  
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1.2. Secondary Active membrane transport 
On the contrary, active transporters require other sources of energy to 
transport their substrate against the electrochemical gradient. Primary transporters use 
adenosine triphosphate (ATP) or other energy forms, such as light, to drive transport. 
The Na+-K+ pump exports sodium ions and imports potassium ions across the 
membrane by consuming the energy from the hydrolysis of ATP to adenosine 
diphosphate (ADP). The Na+-K+ pump keeps the sodium ion concentration to be 145 
mM outside and 5 to 15 mM inside. The membrane potential is maintained under 
normal physiological condition. The electric charge in the cell is kept negative against 
the outside of the cell, in which positively charged ions in the out side of the cell 
move into the negatively charged cell.  
Secondary active transporters use the large electrochemical energy stored in 
the ion gradient, such as Na+ or H+, across the membrane. (Mitchell 1957) For many 
transporters the electrochemical gradient of Na+, set up by the Na+-K+ pump, 
combined with the membrane potential drives the transport of a second molecule. 
Secondary active transporters are categorised into symporters, also called 
cotransporters, and antiporters that transport a second molecule in the same direction 
or in the opposite direction, respectively. For example, the sodium glucose symporter 
(SGLT1) expressed in the small intestine and kidney proximal tubules, transports 
sodium ion and glucose into the cell with the stoichiometry of two sodium ions and 
one glucose	  (Hediger	  et	  al.	  1987;	  Loo	  et	  al.	  2006).  
 
 
 
 9?
1.3. Alternating access model 
The proposed mechanism of secondary active transporter is called the 
alternating access model 6(*0"/ 9A>>2 %&( 9A@:2 &(()*   :8997. 
According to this model transporters have multiple conformations and transport their 
substrate with reversible conformational changes. (Fig. 1.1) First, the substrate 
binding pocket of the transporter is open to one side of the membrane to recognise 
their substrates. Second, followed by the binding of substrate and co-transported ions 
in coupled transporters, the transporter closes the pocket to form the occluded state in 
which the substrates are not accessible to either side of the membrane. Then the 
transporter releases the captured substrate by opening the pocket to the other side of 
the membrane.  
 
 
 
 
 
 
Fig. 1.1. Schematic diagram of alternating access model of secondary active 
transporter. 
Proposed alternating access model. A series of different conformational states during 
coupled transport. (A) Substrate and ion (black star and red sphere) free outward 
facing conformation. (B) Substrate and ion bound outward open conformation. (C) 
Occluded outward facing substrate and ion bound state. (D) Occluded substrate and 
ion bound intermediate state. (E) Occluded inward facing substrate ion bound state. 
(F) Substrate and ion bound inward open state. (G) Substrate ion free inward open 
conformation. Adapted from (Forrest et al. 2011) 
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This transport model has been supported by various X-ray crystal structures of 
transporters in different conformations. For example the LeuT fold proteins, LeuT 
(Yamashita et al. 2005; Krishnamurthy and Gouaux 2012; Kazmier et al. 2014), 
Mhp1 (Suzuki and Henderson 2006; Weyand et al. 2008; Shimamura et al. 2010) and 
BetP (Perez et al. 2011; Perez et al. 2012; Perez et al. 2014). Although these 
transporters belong to different families and their sequences are not similar each other, 
they are structurally homologous. The LeuT fold motif is composed of an inverted 
repeat of two sets of five transmembrane helices. (Fig. 1.2.) The repeated domains are 
related by a 2-fold symmetry axis. The ion and substrate binding sites are located at 
the centre of the membrane where two transmembrane helices are unwound.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 9A
 
 
 
 
 
 
 
 
 
 
Fig. 1.2. Schematic diagram of LeuT. 
Cartoon representation of LeuT oriented with the periplasm on top. The helices are 
coloured to depict TMs 1 to 12 and grouped by domain. Pink and light blue trapezoids 
indicate inverted repeat motifs. TM1 to 5 and TM6 to10 are pseudo-symmetry related 
to each other.  
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The sodium benzyl hydantoin transporter (Mhp1) from Microbacterium liquefaciens 
is the secondary active transporter belonged to nucleobase cation symport family and 
transports 5-aryl-substituted hydantoins into the bacterial cells sodium dependently	  (Suzuki	   and	   Henderson	   2006;	   Weyand	   et	   al.	   2008). X-ray crystal structures of 
Mhp1 were solved with different conformations, the outward facing, the occluded 
states and the inward facing conformation	   (Weyand	  et	  al.	   2008;	   Shimamura	  et	  al.	  2010).	  These structures, and molecular dynamics simulations, elucidated the transport 
cycles of Mhp1. Mhp1 is composed of twelve transmembrane helices (TMs) with the 
N-terminal five TMs and the second five TMs forming inverted motifs. Each domain 
is related by a pseudo 2-fold axis perpendicular to the middle of the membrane. These 
TMs are further categorized into three parts, bundle motif (TM1, TM2, TM6 and 
TM7), flexible helices (TM3, TM5, TM8 and TM10) and hash motif (TM3, TM4, 
TM8 and TM9) (Fig. 1.3.). The conformational change from the outward facing to 
inward facing could be explained by the rigid body movement of the hash motif in 
which relative rotation around the bundle motif could be observed. As the other 
secondary transporters also has a similar fold, this transporting mechanism would be 
applied for them as well. However, detailed structural information such as substrate 
recognition and intermediate conformations are necessary to understand respective 
transporter’s function precisely. Due to the difficulty of X-ray crystallography of 
experimentally unstable membrane transporter, it is difficult to obtain the structures in 
different conformation.  
 
 
 
 
 :9
 
 
 
 
 
 
 
 
 
Fig. 1.3. Schematic illustration of the Mhp1. 
Cartoon representation of Mhp1 oriented with the periplasm on top. The blue 
rectangle represents the bundle composed of TM1, TM2, TM6 and TM7. The pink 
and yellow represent the thin gate and hash motif respectively. Sodium ion and benzyl 
hydantoin are shown as red sphere and green star. A). Outward facing conformation. 
B). Occluded conformation. C). Inward facing conformation. 
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1.4. Bile acids and the Enterohepatic circulation 
Bile acids are synthesized from cholesterol in the liver. After they have been 
synthesised, bile acids are stored in the gallbladder and, after a meal, transferred to the 
ileum through the duodenum and the jejunum. In the small intestine bile acids help 
the processing of fat-soluble organic compounds including dietary fat, fat-soluble 
vitamins (vitamin A, D, E and K) and lipids by emulsifying them and forming 
micelles (Hofmann 1962). Most of the bile acids secreted into the small intestine are 
reabsorbed by active transport in the ileum cell and transported back to the liver or 
gallbladder via the portal blood stream. This system, called enterohepatic circulation 
(EHC), is highly effective and about 95% of bile acids are recycled. (Fig. 1.2) The 
rest of the bile acids are removed with faeces and replaced by newly synthesised bile 
acid from cholesterol in the liver. Approximately 500 mg of cholesterol are consumed 
to produce new bile acids every day in the human body. (Carey 1982). 
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Fig. 1.2. Enterohepatic circulation of bile acids. 
Bile acids are synthesized in the liver and exported to bile duct through BSEP and/or 
MRP2 by consuming ATP as an energy source. Bile acids are secreted into the 
intestine and reabsorbed in the ileum cell by ASBT in a sodium dependent manner. 
Reabsorbed bile acids are transported by OST from the ileum to the portal blood then 
returned to the hepatocyte through NTCP and/or OATP.  
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Bile acids are amphipathic molecules composed of a hydrophobic steroid 
structure and hydrophilic carbon side chains terminating in a carboxylic acid. With 
this amphipathic character, bile acids can work as detergents and form micelles in the 
intestine to help digestion of insoluble materials. Bile acids are categorised into 
primary and secondary bile acids. (Fig. 1.3) Cholesterol is converted to primary bile 
acids through microsomal cytochrome P450 mediated synthesis steps including 
synthesis of sterol precursors, modifications to the ring structures and oxidation and 
shortening of the side chain (Jelinek et al. 1990; Russell 2003). Various enzymes 
correspond to these processes as described below. 7α-hydroxylases catalyse 
hydroxylation of cholesterol at different positions. (Javitt 2000) Then, C27 3β-HSD 
catalyses the modification of the ring structure (Wikvall 1981; Furster et al. 1996; 
Schwarz et al. 2000) followed by side chain oxidation and shortening by sterol 27-
hydroxylase (Andersson et al. 1989; Dahlback and Holmberg 1990; Pikuleva et al. 
1998). These primary bile acids include cholic acid and chenodeoxycholic acid. In 
humans, cholic acid is the primary bile acid constituting about 80% of bile acids. 
Since cholic acids are poorly soluble at physiological pH in the small intestine, they 
are usually conjugated with taurine or glycine molecules to give taurocholic acid and 
glycocholic acid respectively (Falany et al. 1994; Solaas et al. 2000). These 
conjugated bile acids are called secondary bile acids. The conjugation reaction is 
catalysed by the bile acid coenzyme A, amino acid N-acyltransferease enzyme. 
Additionally, primary bile acids are metabolized into secondary bile acids by the 
anaerobic bacteria in the gut, where cholic acid and chenodeoxycholic acid are 
converted to deoxycholic acid and lithocholic acid respectively (Hylemon and Harder 
1998). At physiological pH these conjugated states are more soluble than 
unconjugated states and by preventing passive re-absorption from the small intestine 
	   25	  
can maintain enough high concentrations for emulsifying fat or lipids. Furthermore, 
conjugated states of bile acids are more ionized than unconjugated states at an 
intestinal pH value, which could emulsify fats more efficiently (Hofmann 1999).  
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Fig. 1.3. Bile acid synthesis from cholesterol, conjugation and dehydroxylation 
process in human body.  
Cholesterol is converted into cholic acid or chenodeoxycholic acid, primary bile acids, 
mediated by cytochrome P450 synthesis steps. Cholic acids are catalysed by 
coenzyme A and conjugated with taurine or glycine to taurocholic acid and 
glycocholic acid respectively. Cholic acids and chenodeoxycholic acid are 
metabolized by bacteria in gut to deoxycholic acid and lithocholic acid respectively. 
Glycocholic acid, deoxycholic acid, taurocholic acid and lithocholic acid are called as 
secondary bile acid. 
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1.5. Transporters in Enterohepatic circulation 
Many transporters work together to maintain enterohepatic circulation as 
uptake or efflux gates in the liver hepatocyte cells and/or in the intestine ilium cells 
(Alrefai and Gill 2007). As conjugated states of bile acids, for example taurocholic 
acid, are soluble at physiological pH, they cannot pass through cell membranes by 
diffusion. Thus, membrane transporters are indispensable for bile acid flow between 
the liver and the small intestine.  
 
1.5.1. Hepatocyte cell 
Uptake transporters 
Bile acids are transported from the portal blood to the liver by the transporters on the 
sinusoidal membrane of the hepatocyte (Meier 1995), mainly by OATPs and NTCP	  (Hagenbuch	  and	  Meier	  1994;	  Kullak-­‐Ublick	  et	  al.	  1995).  
Sodium Taurocholate Co-transporting Peptide (NTCP: SLC10A1) is 
expressed in the basolateral membranes of the hepatocytes and allows the sodium 
dependent uptake of bile acids from the portal blood into the hepatocyte	  (Shiao	  et	  al.	  2000;	  Geyer	   et	  al.	   2006). NTCP transports both conjugated and unconjugated bile 
acids in a sodium symport manner with a stoichiometry of one bile acid and two 
sodium ions	  (Schroeder et al. 1998).  
Organic Anion Transporting Peptide (OATP) also transports bile acids but 
does not require the sodium gradient as a driving force	   (Trauner and Boyer 2003). 
OATPs have several orthologs including OATP1A2, OATP1B1 and OATP1B3	  (Tamai	  et	  al.	  2000;	  Wang	  et	  al.	  2012). OATP1A2 and OATP1B3 are expressed in 
the brain and liver with better expression in the brain	   (Kullak-Ublick et al. 1995). 
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OATP1B1 is only expressed in the basolateral membrane of the hepatocytes	   (Konig	  
et	   al.	   2000;	   Hagenbuch	   and	   Meier	   2004). OATPs transport amphipathic organic 
compounds including unconjugated states of bile acids	  (Meier 1995).  
 
Export transporter 
Both recycled and newly synthesised bile acids are exported from the hepatocyte to 
the bile duct across the canalicular membrane against a steep concentration gradient. 
MRP2 and BSEP are the major transporters responsible for bile acid uptake across the 
canalicular membrane	  (Buchler	  et	  al.	  1996;	  Gerloff	  et	  al.	  1998). They use the energy 
involved in the hydrolysis of ATP to transport bile acids with distinct specificities; 
MRP2 transports divalent bile acids (sulphated taurocholic acid and glycolithocholic 
acid) and BSEP transports monovalent (taurocholic acid and glycocholic acid).  
Multidrug Resistance associated Protein (MRP2) is expressed in the 
canalicular membrane and has a wide variety of substrate specificity including 
divalent bile acids such as sulfated taurocholic acid and glycolithocholic acid but does 
not transport monovalent bile acids; taurocholic acids	  (Ito	  et	  al.	  2001;	  Trauner	  and	  Boyer	  2003).  
Bile Salt Export Protein (BSEP) is also expressed in the canalicular membrane 
and transports conjugated monovalent bile acids, such as taurochenodeoxycholic 
acids and taurocholic acids	  (Byrne	  et	  al.	  2002;	  Noe	  et	  al.	  2002).  
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1.5.2. Ileum cell 
After the secretion from the liver, bile acids function in the intestine to help 
process fat-soluble compounds. Most bile acids, both conjugated and unconjugated, 
are reabsorbed in the intestinal lumen and are transported back to the liver via the 
portal blood. Two membrane transporters are involved as described below.  
Apical Sodium Dependent Transporter (ASBT: SLC10A2) is responsible for 
the uptake of bile acids from the apical membrane of the ileum cell. ASBT requires 
only the sodium ion gradient and the negative intracellular potential for its function	  
(Weinman et al. 1998). Two sodium ions are transported for every bile acid. Both 
conjugated and unconjugated states of bile acids are transported by ASBT; cholic acid, 
deoxycholic acid and chenodeoxycholic acid as unconjugated bile acids and taurine 
and glycine conjugated states of those bile acids	  (Craddock et al. 1998). 
Organic Solute Transporter (OSTα-OSTβ) is localized in the basolateral 
membrane of the ileal enterocyte and transports bile acids into the portal blood 
independently of the sodium ion gradient. Two different subunits of OSTα and OSTβ 
are co-expressed and functional as a complex	   (Dawson	  et	  al.	  2005;	  Li	  et	  al.	  2007). 
They transport not only bile acids but also other compounds including estrone-3-
sulfate, digoxin and prostaglandin E2 (PGE2)	   (Ballatori et al. 2005). The detailed 
transport mechanism of OSTα-OSTβ has not yet been revealed. 
Although these bile acid transporters have critical roles in the enterohepatic 
circulation, their precise characters are not yet well studied including substrate 
recognition and mechanism of transport. Further studies are required to accumulate 
more information about how the lipids and cholesterol homeostasis are maintained in 
the human body.  
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1.6. SLC10 family 
 Among these transporters, NTCP and ASBT belong to the SLC10 family. The 
solute carrier (SLC) families comprise 51 families and a total of 378 human 
transporter genes have been identified (White et al. 1997) (Table. 1.1.), including 
passive transporters, ion-coupled symporters and antiporters. The solute carrier family 
10 (SLC10), called sodium/bile salt co-transport family, contains 7 transporters, Na+/ 
taurocholate co-transporting polypeptide (NTCP; SLC10A1), apical sodium-
dependent bile acid transporter (ASBT; SLC10A2), SLC10A3, SLC10A4 (Geyer et al. 
2008; Burger et al. 2011; Abe et al. 2013), SLC10A5 (Fernandes et al. 2007), 
sodium-dependent organic anion transporter (SOAT; SLC10A6) (Geyer et al. 2007)  
and SLC10A7 (Godoy et al. 2007). The substrates of only three of these transporters 
NTCP, ASBT and SOAT are currently known. The other member of SLC10 family 
are not well characterised. Among these members, NTCP and ASBT play pivotal 
roles in hepatic and intestinal bile acid uptake respectively as described above	  (Weinman	   1997;	   Weinman	   et	   al.	   1998). Although, these transporters show high 
identities to each other from 18% to 60% and possess highly conserved functionally 
important residues, their substrate specificities vary (Geter et al. 2006). Thus, 
investigations of each transporter are essential to distinguish their detailed transport 
mechanisms and would help design specific inhibitors. 
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Table. 1.1. SLC10 family 
Human gene 
name 
Protein 
name 
Substrate Transport 
coupling ions 
Localization 
SLC10A1 NTCP Bile acid C / Na+ Liver, Panceas 
SLC10A2 ASBT Bile acid C / Na+ Ilium, Kidney, Biliary 
tract 
SLC10A3 P3  O Ubiquitous 
SLC10A4 P4  O Brain, Placenta, Liver 
SLC10A5 P5  O Liver, Kidney 
SLC10A6 SOAT Sulfate C / Na+ Testis, Placenta, 
Pancreas 
SLC10A7 P7  O Liver, Testis 
Adapted from HUGO Nomenclature Committee	   (White et al. 1997). C: 
Cotransporter; O: Orphan transporter  
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1.7. Aim of this study 
The aim of my research was to determine the X-ray crystal structures of 
membrane transporters involved in the transport of bile acids to investigate their 
mechanisms. I wanted to examine the Apical Sodium-dependent Bile acid Transporter 
(ASBT). As the crystallisation of human membrane proteins is extremely difficult I 
used a homologue of ASBT to understand the human protein. The structure of this 
protein was previously solved in our lab (Hu et al. 2011). In this thesis I investigate 
the mechanism further with structures of mutants coupled with characterisation using 
biochemical and biophysical assays.  
ASBT transports bile acids through the apical membrane of the ileum into the 
portal blood as discussed above. Loss of functional mutation of ASBT has been 
reported to related to several diseases. Single point mutation from a proline to serine 
at position 290 resulted in loss of transport activity of taurocholic acid and this 
substitution was identified in a patient with Crohn’s disease	   (Wong et al. 1995). 
L243P and T262M mutations lead to Primary Bile Acid Malabsorption (PBAM)	  (Heubi	  et	  al.	  1982;	  Oelkers	  et	  al.	  1997). It is also a pharmaceutical target for drugs 
aimed at lowering cholesterol and several ASBT inhibitors have been developed 
which can significantly lower plasma levels of cholesterol in animal models	  (Kurata	  
et	  al.	   2004;	  Chen	  et	  al.	   2012;	  Liu	  et	  al.	   2013). The rationale for this is that if the 
transporter is blocked with specific inhibitors, the concentration of bile acids 
returning to the liver decreases. To keep the homeostasis of bile acids concentration in 
the body, more bile acids are synthesizd from cholesterol resulting in lowering the 
cholesterol level in the body	  (West	  et	  al.	  2002;	  Braun	  et	  al.	  2008).  
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Fig. 1.4. Sequence alignment of ASBTNM to human ASBT and human NTCP. 
Sequence alinement of ASBTNM (UniPort ID: Q9K0A9) to the human ASBT 
(UniPort ID: Q12908) and human NTCP (UniPort ID: Q14973) using ClustalW2 
(www.ebi.ac.uk/Tools/msa/clustalw2/) and figure preparation in JalView(Waterhouse 
et al. 2009). The sequence identity of ASBTNM to human ASBT and human NTCP is 
26% and 23% respectively as calculated using pairwise alignment in JalView. The 
coloured bars depict the location of the transmembrane α-helices in ASBTNM. 
Residues forming Na1 and Na2 binding sites are highlighted as blue and red boxes 
and inward facing open pocket as pink.   
 
 
 
 
 
	   34	  
The X-ray crystal structure of a bacterial homologue of ASBT was solved in 
our lab at 2.2Å. (Hu et al. 2011) This transporter was from Neisseria meningitides and 
has 26% sequence identity to human ASBT. (Fig. 1.4) Functionally important 
residues in mammalian ASBT are conserved in this ASBT homologue. Though 
physiologically the transporter is unlikely to transport bile acids, it may transport a 
similar molecule. The transport activity of taurocholic acid has been measured and 
gives a similar Km value to that of human ASBT (Around 50 µM). Thus, this protein 
is a good model for which to study mammalian bile acid transporters. ASBTNM has 
ten transmembrane helices and is composed of two inverted structural repeat of five 
transmembrane helices in a similar fashion to LeuT though there is no structural 
similarity (Fig. 1.5.) The protein contains two domains, the core and the panel domain 
made up by intertwining of the repeat motif. The Core domain of six helices has two 
highly conserved sodium ion binding sites. Taurocholic acid is bound in the inward 
facing open pocket between core domain and panel domain of four helices. (Fig. 1.6.) 
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Fig. 1.5. Schematic diagram of the ASBTNM topology. 
Cartoon representation of ASBTNM oriented with the periplasm on top. The helices 
are coloured to depict TMs 1 to 10 (same as Fig. 1.4.) and grouped by domain. Pink 
and light blue trapezoids indicate inverted repeat motifs, TM1 to 5 and TM6 to10 are 
psudo-symmetry related each other. Respective pink and light blue motifs form core 
domain and panel domain.   
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Fig. 1.6. Ribbon style representation of ASBTNM structure. 
ASBTNM structure (3ZUY) is represented as ribbon style using PyMOL (Schrödinger, 
LLC). The colours of helices are the same as Fig. 1.4. and Fig. 1.5. Left: Viewed in 
the plane of the membrane. TM2 to 6 and TM8 to 10 form the core domain and TM1 
to 2 and TM6 to 7 form the panel domain. The red sphere indicates Na2 and blue 
sphere indicates Na1. Taurocholic acid is represented as a stick model. Right: 
ASBTNM viewed from the intracellular side.  
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Fig. 1.7. The inward facing pocket of ASBTNM (3ZUY)  
a. Inward facing open pocket. The inward facing pocket consists of hydrophobic 
residues, Phe15, Leu47 Ala113, Val116, Met117, Leu120, Pro196, Ser199, Val200 
and Ile203.   b. Taurocholic acid binding residues in ASBTNM inward facing open 
pocket. Thr112 and Asn295 form hydrogen bonding with taurocholic acid. Both 
Asn265 and His294 interact with taurocholic acid via water molecules. c. Na1 binding 
site in ASBTNM. The side chains of Ser114, Asn115, Ser128, Thr132 and E260 
interact with Na1. The backbone of Ser128 interacts with Na1. d. Na2 binding site in 
ASBTNM. The side chains of Gln77 and Gln264 interact with Na2. The backbones of 
Val261 and Met263 interact with Na2.  
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From the WT ASBTNM structure in complex with taurocholic acid some key 
residues were identified as being involved in substrate recognition (taurocholic acid in 
this structure) and sodium (Na1 and Na2) binding. (Fig. 1.7) T112, N265, H294 and 
N295 interact with substrate surrounded by hydrophobic residues, F15, I47, A113, 
M117, L120, P196, S119 and V200. S114, N115, S128, T132 and E260 interact with 
Na1 and Q77, Q264 and backbone of E260 and M263 interact with Na2. However, 
the detailed transport mechanism is not clear yet. According to the alternating access 
model, ASBTNM would change the conformation from outward to inward facing 
conformation by the rigid body movement of the panel domain and the core domain. 
In this structure, ASBTNM would represent the intermediate state of just before 
releasing the substrate and/or sodium ion. This structure was obtained under the 
crystallization condition that is not the same as cell environment including excess 
amount of taurocholic acid and the lack of the sodium gradient and the membrane 
potential. There was no structure of an outward facing conformation and the 
recognition of the substrate or the roles of the two sodium ions in the transport 
pathway were not evident. There are a number of ways that this can be investigated. 
One way is through site-directed mutagenesis approaches, preferably combining this 
with crystallography. Another way is to determine the structure in complex with other 
compounds that may bind to ASBTNM and trap the protein in different conformations. 
As sodium ions could hold ASBTNM in a particular conformation, removing sodium 
ions from ASBTNM could change the conformation of the protein. However, removing 
sodium ions from the system is practically difficult as they are included in the cell 
culture media and purification buffers to keep ASBTNM stable. Instead of removing 
sodium ions from the system, mutation of sodium binding residues is introduced to 
exclude functionally important ions. A similar approach was used for LeuT. The 
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structure of LeuT, a bacterial homolog of the neurotransmitter sodium symporters 
(NSSs), has been solved in different conformations, outward and inward facing 
(Kazmier et al. 2014). Firstly, outward facing occluded conformation was solved in 
complex with its substrate and two sodium ions	   (Yamashita et al. 2005). Secondly, 
outward facing open conformation was solved in complex with the competitive 
inhibitor and two sodium ions. Lastly, inward facing open conformation was solved in 
which sodium binding residues were mutated (Krishnamurthy and Gouaux 2012). 
Thus, the mutagenesis approaches targeting sodium ion binding site would be an 
appropriate strategy to obtain the different conformation of the secondary active 
transporters. 
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CHAPTER 2 
 
Biochemical and Biophysical methods 
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2.1. Membrane protein crystallography 
In order to express membrane proteins abundantly, it is necessary to examine a 
large variety of conditions including homologues of the protein in different species, 
constructs of amino acids sequence and suitable detergents. The GFP-fusion system 
(Drew et al. 2006; Kawate and Gouaux 2006) enables many constructs to be screened 
within quite a short time. The method works by adding green fluorescence protein 
(GFP), to the C-terminus of the target membrane protein construct. Then, if the 
membrane protein expresses and is correctly introduced into the cellular membrane, 
GFP will also be expressed. As the amount of GFP expressed can be determined by 
measuring the fluorescence counts this provides a direct readout of the amount of 
target protein. The expression level of the membrane protein can be estimated by 
counting the fluorescence level of GFP from cell culture solution without harvesting 
or solubilising the cells. Furthermore, this fluorescence can be used to analyze the 
monodispersity and stability of the target membrane proteins in complex with a series 
of detergents using size exclusion chromatography, named Fluorescence Size 
Exclusion Chromatography (FSEC). Traditional experimental methods usually need a 
lot of time and effort to screen expression levels and detergent selection compared to 
this rapid and efficient method. Consequently, this is a successful method (Jasti et al. 
2007; Kawate et al. 2009; Shaffer et al. 2009; Sobolevsky et al. 2009; Tao et al. 
2009; Feng et al. 2010; Tang et al. 2010). Although some difficulties have been 
overcome with developments of techniques like this GFP-fusion system, structural 
determination of membrane proteins is still difficult and we need to make more effort 
and dedication to solve them.  
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2.1.1. Crystallography 
X-ray crystallography gives the most detailed information about the protein 
structure at the resolution of individual atoms. The protein molecule is composed of a 
chain of amino acids residues in which length of bonded atoms are less than around 
1.5 Å. Whereas this range of length is too short for the visible light, wavelengths of 
400 – 700 nm, to observe the object, X-rays are capable to be diffracted from the 
individual atoms, 1 pm – 10 nm. When X-rays pass through the protein, X-rays 
diffracted as a result of the interaction with the electrons of the atoms. Since the 
signal from a single molecule is too weak to be detected, protein crystals are required 
that contains many ordered molecules where each signal from one protein is 
reinforced by the signal from the others. The X-ray diffraction pattern from the crystal 
can be recorded on a detector as discrete reflections. The atomic information of the 
protein is related to the diffraction pattern in a mathematical manner termed the 
Fourier transform. As X-rays cannot be focussed sufficiently to recombine the 
diffracted X-rays, to obtain the atomic structure an inverse Fourier transform is 
performed by computer using the directions and intensities of diffracted X-rays.  
The X-ray crystal structure gives powerful information with its precise 
descriptions of the protein structure at an atomic level. In spite of its importance for 
living cells, structural information of membrane proteins is limited with less than 495 
unique membrane proteins submitted among over 102,720 proteins in the Protein 
Data Bank at Aug2014. (http://www.rcsb.org/, http://blanco.biomol.uci.edu/mpstruc/)  
The reason for the low amount of structures solved is due to the extreme difficulty in 
handling the protein experimentally. Since membrane proteins are surrounded by 
hydrophobic tails of phospholipids in the membrane, the surface of their 
transmembrane domains are also composed of hydrophobic residues and so the 
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proteins are poorly soluble and unstable in water when removed from the membrane. 
This insoluble character makes it difficult for the experimental procedures of X-ray 
crystallography, purification and crystallization.  To solve this problem the membrane 
proteins are usually solubilized with detergents. The hydrophobic tails of the 
detergent surround the protein so that it is stabilized and can be treated as a general 
soluble protein during the purification and crystallization steps by keeping the 
required concentration of detergents.  However, selecting the ideal detergent for a 
target protein from various kinds of detergents often requires researchers to spend a 
lot of time and energy. For these reasons, membrane proteins are still regarded as 
some of the most difficult targets in the field of X-ray crystallography. 
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2.1.2. Crystallization in detergent 
Membrane proteins composed of large hydrophobic surface require detergent 
molecule to be stabilized in solution. However, these detergent molecules and their 
formation of micelles occupy a large amount of the surface region of the membrane 
protein preventing sufficient protein-protein contacts for forming protein crystals. 
Furthermore, the choice of the detergents used for the crystallization is important. 
DDM is the most popular detergent for solubilization, purification and even 
crystallization. Although crystallization with DDM often gives membrane protein 
crystals, the crystals obtained generally do not diffract well due to its large micelle 
size	  (Sonoda et al. 2011). Use of detergents with a smaller micelle size than DDM can 
give better diffracting crystals	  (Sonoda et al. 2011). For example, LDAO was used for 
solving the ASBTNM structure at the resolution of 2.2 Å. In spite of the benefit from 
small detergents, they are too harsh for many membrane proteins and destabilize them. 
Thus, the membrane protein should be stable enough so that crystal can be obtained 
under the harsh small detergent.  
The most popular technique for crystallization is the vapour diffusion method, 
in which two variations are usually used, sitting drop and hanging drop. The small 
amount of concentrated protein is aliquot to the glass or plastic well and mixed with 
reservoir solution to a final ratio of 1:1. Then crystallization drop is sealed in a closed 
well which contains an excess amount of the reservoir solution and incubated at 4 °C 
or 20 °C. The concentration of the precipitant solution in the crystallization drop is 
about half of the original condition. In the closed system, the crystallization drop 
starts evaporating by the solute concentration gradient against the reservoir. During 
the evaporation, concentrations of the protein increase leading to the formation of the 
protein crystal nuclei if the condition is ideal for the protein. 
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2.1.2. Lipidic cubic phase method of crystallisation 
The lipidic cubic phase crystallization is a unique method for membrane 
protein that has been developed relatively recently compared to the vapour diffusion 
method	   (Cheng et al. 1998; Cherezov et al. 2002; Caffrey and Cherezov 2009; 
Aherne et al. 2012). Examples of successful crystallisation have been reported from 
various membrane proteins such as β-barrel membrane proteins	  (Cherezov et al. 2006; 
Cherezov et al. 2008), α-helical membrane proteins	  (Schobert et al. 2002; Cherezov et 
al. 2006; Gmelin et al. 2007; Wohri et al. 2009; Tiefenbrunn et al. 2011) and, 
especially GPCRs	  (Granier et al. 2012; Kruse et al. 2012; Liu et al. 2012; Manglik et 
al. 2012; Wu et al. 2012; Zhang et al. 2012; Hollenstein et al. 2013; Tan et al. 2013; 
Wang et al. 2013; Dore et al. 2014). At a distinct temperature and lipid to water ratio, 
the lipid forms a cubic phase that is composed of a lipid bilayer. Monoolein is the 
most popular lipid for LCP and well studied so far. The cubic mesophase is formed at 
20 °C at a water monoolein composition of around 40% (wt/wt) water. When purified 
membrane proteins are mixed with this LCP, they reconstitute into a curved lipid 
bilayer forming a viscous and sticky LCP. This could eliminate detergent molecules 
and micelle from around the membrane protein. The mixture of LCP and membrane 
protein is then dispensed onto the glass plate and the crystallization precipitant is 
added onto the LCP and sandwiched by a thin glass cover. Components of the 
precipitants could diffuse into the LCP by passing through water pores, destabilize the 
cubic phase and lead to phase transitions and separations, which could cause 
nucleation of a protein crystal and further crystal growthing. Owing to the tight 
packing, the diffraction data is also of higher quality. Although the LCP method is a 
powerful technique for membrane protein crystallization, some difficulties still exist 
as described below.  
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Size of crystal  
Except for some examples, LCP crystals are generally tiny around 1 to 50 µm 
size. Together with the viscous and half transparent character of LCP, this size of 
crystal is difficult to observe under the microscope without a cross polarizer lens. 
Because of the small size of crystals microfocus beamlines are essential to collect data, 
otherwise normal beam size is too big to shoot tiny crystal. Additionally, small 
crystals do not survive long enough to collect a full data set using a high energy 
synchrotron beam. Thus, multiple data sets from LCP crystals must be merged to give 
a complete data set. It is also necessary to perform grid scanning diffraction image 
collection, to find out where the LCP crystal is located in the non-transparent LCP 
droplet on the loop. Grids of 10 to 300 images are used to cover the loop. To achieve 
these purposes fast speed image reading detector is desirable, for example the 
PILATUS (Broennimann et al. 2006) detector is useful for collecting data quickly. 
 
Fishing the crystal  
The LCP crystallization plate is a sandwich glass plate composed of a base 
glass and a cover glass. When fishing the crystal from the well, the cover glass has to 
be cut by manually using glass cuter. Experience is required to open the cover glass 
without damaging the crystal. It is also often observed that once the cover glass has 
been opened the cubic phase starts to change its phase and dissolve in the reservoir. 
Thus, crystals should be fished as soon as possible after opening the cover glass.  
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In the absence of the structure there are other biophysical techniques that can be used.  
 
2.2. Isothermal Titration Calorimetry (ITC) 
Isothermal Titration Calorimetry (ITC) can detect heat changes when a ligand 
binds to a protein and is the one of the most precise technique for characterization of 
molecular interactions in solution	   (Freyer and Lewis). This technique has been used 
not only for soluble proteins but also for membrane proteins	   (Lockless	  et	  al.	  2007;	  Maes	  et	  al.	  2012;	  Picollo	  et	  al.	  2012;	  Striegel	  et	  al.	  2012;	  Rajarathnam	  and	  Rosgen	  2014).	   The binding enthalpy is determined as the change of heat for reversible 
interactions. Furthermore, the equilibrium binding constant (KD) and the 
stoichiometry of the interaction can be calculated from the titration curve. Then, the 
entropy change (ΔS) and the Gibbs free energy (ΔG) are calculated from the KD value 
and the enthalpy change (ΔH). The reaction is measured in solution without any 
labelling of either the protein or the ligand. That information can be used to 
characterise the substrate and the inhibitor and help to design more potent inhibitors	  (Freire	  2008;	  Ladbury	  et	  al.	  2010).  
                                            
 
R: Gas constant, K: Absolute temperature, 
 
 
 
 
ΔG = - RT ln KD  
ΔG = ΔH - TΔS 
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2.3. Microscale Thermophoresis (MST) 
Microscale Thermophoresis (MST) is a relatively new technique compared to 
other biochemical and biophysical techniques	   (Stumpfe	  et	  al.	  2010;	  Wienken	  et	  al.	  2010;	   Jerabek-­‐Willemsen	   et	   al.	   2011;	   Seidel	   et	   al.	   2012).	   The principle of this 
method is unique in that it measures the molecular interaction from the change of the 
hydration shell of molecules as described below. Protein solutions are mixed with 
serial concentrations of a ligand in capillaries. Either the protein or the ligand is 
tagged by a fluorescent label. Each sample is heated by a focused infrared laser (IR) 
and the fluorescence of the sample is monitored. The molecules in the system are 
displaced by the temperature gradient	  (Duhr and Braun 2006). This motion is related 
to the solvation entropy and the hydration shell of the protein that is changed by 
binding the ligand. The binding affinity of the ligand can be determined by measuring 
the difference in fluorescence in each of the ligand concentrations. This technique has 
been applied for membrane protein characterization as well	   (Parker	  and	  Newstead	  2014;	  Srinivasan	  et	  al.	  2014).	   
 
 
  
 
 
 
  
 
 
 
	   49	  
2.4. Circular Dichroism (CD) 
Circular dichroism (CD) is the differential absorption of left-handed and right 
handed circularly polarized light. It occurs when a chiral material, such as a protein 
molecule, absorbs circularly polarized light. CD spectroscopy is used to investigate 
secondary and tertiary structures of proteins. Synchrotron radiation circular dichroism 
(SRCD) is much brighter than that obtained with a bench-top CD instrument. This 
enables data with a high signal to noise to be collected with reasonably little amount 
of protein samples	  (Javorfi et al. 2010). The near UV (250-330nm) region is sensitive 
to the tertiary structure of aromatic residues of the protein, phenylalanine, tyrosine 
and tryptophan. In far UV region (170-260nm), the secondary structure of the protein, 
alpha helices and beta sheets, can be determined. As disruption of the secondary 
structure reflects unfolding of the protein, it gives information about the stability of 
the protein from thermal denaturation and/or UV denaturation	   (Clarke and Jones 
2004; Wien et al. 2005).  
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2.5. Transport assays 
Several approaches to measure the binding affinity of ligand are described 
above, in which detailed quantitative parameters of binding reaction can be obtained. 
These assays do not give information about transport. In addition to the binding 
affinity, the transport activity is also indispensible. Specifically for membrane 
transporters, transport activity should be evaluated carefully, since it is different from 
the binding affinity of the substrates. The assays described above are carried out 
under solution, thus transporter are required to be solubilised in detergent buffer. 
While these techniques give highly valuable information, they differ from actual 
transport situation such as lipidic environment around the protein and sodium and 
electrochemical potential gradients across the membrane. Transport assays can be 
carried out either in cells or in proteoliposomes. 
In this thesis the cell-based assay uses E.coli cells harbouring ASBTNM. This 
is a reasonably rapid system as there is no need for purification and E.coli expression 
takes only a few days. However, cells contains various factors, which cannot be 
controlled, including a wide variety of membrane proteins and some of them might be 
capable to uptake/export bile acid across the membrane. On the other hand, transport 
assay by using proteoliposome demands purification of the protein and preparation of 
the proteoliposome, in which more accurate controls of molecular ratio of the protein 
and reproducible results are available. When the lipid is dissolved in the water, owing 
to their extremely low critical micelle concentrations and water solubility, lipids self-
assemble into bimolecular lipid leaflets exposing hydrophilic head group to aqueous 
phase and facing hydrophobic tail group each other in the core of the bilayer by 
hydrophobic effect (Gregoriadis 2007). Then, lipid bilayers form large and 
multilamellar vesicles (MLV) to reduce contact between water phase and 
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hydrophobic core of the bilyer at the edge (Gregoriadis 2007). Formed MLV are 
converted to single unilamellar vesicles (SUV) by sonication. Generally disruption of 
MLV is achieved by sonication with diameters in the range of 15-50 nm (Weissig 
2010). One disadvantage of the proteoliposme method is that it is difficult to control 
the orientation of the protein in the liposome and this can lead to artifacts. 
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CHAPTER 3 
 
Methods 
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3.1. Expression and Purification 
3.1.1. Preparation of mutants 
ASBTNM mutants were cloned as GFP-His8 fusions into the pET28 (a) 
derivative vector pWaldoGFPe (Drew et al. 2006). ASBTNM mutants were 
overexpressed in Escherichia coli cells (C43 and Lemo21). (Schlegel et al. 2012) The 
plasmid encodes the ASBTNM sequence, a cleavage site for TEV, GFP and a His8 tag. 
If the membrane protein expresses and is correctly introduced into the cellular 
membrane, GFP will give fluorescence. The expression levels of ASBTNM mutants 
were estimated by measuring the fluorescence of GFP (emission at 512 nm and 
excitation at 485 nm) from cell culture solution. GFP and His8 tag can be removed by 
TEV protease cleavage at the recognition site, (ENLYFQGQ), inserted between the 
C-terminus of ASBTNM and the N-terminus of GFP. 
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ASBTNM amino acid sequence; 329 aas, 33,875 Da 
MNILSKISSFIGKTFSLWAALFAAAAFFAPDTFKWAGPYIPWLLGIIMFGMGLT 
LKPSDFDILFKHPKVVIIGVIAQFAIMPATAWLLSKLLNLPAEIAVGVILVGCCP 
GGTASNVMTYLARGNVALSVAVTSVSTLISPLLTPAIFLMLAGEMLEIQAAG 
MLMSIVKMVLLPIVLGLIVHKVLGSKTEKLTDALPLVSVAAIVLIIGAVVGAS 
KGKIMESGLLIFAVVVLHNGIGYLLGFFAAKWTGLPYDAQKTLTIEVGMQNS 
GLAAALAAAHFAAAPVVAVPGALFSVWHNISGSLLATYWAAKAGKHKKPG 
SENLYFQ 
 
Primers were designed for each mutant. Mutants of ASBTNM were prepared by 
using the QuickChange Lightning Site-Directed Mutagenesis Kit (Stratagene) as 
below. (Table. 3.1) The PCR reaction was carried out in 0.5 mL PCR tubes in a 
thermal cycler. 1.2 µl of designed forward and reverse primers (10 µM) were mixed 
with 100 ng of WT ASBTNM plasmid DNA, 5 µl of 10x reaction buffer, 1 µl of dNTP 
mix and ddH2O was added to a final volume of 50 µl. 1 µl of PfuTurbo DNA 
polymerase (2.5 U/µl) was then added and the solution gently mixed. The PCR 
reaction was started with 1 cycle at 95 °C for 2 min, 18 cycles at 95 °C for 20 seconds, 
58 °C for 10 seconds and 68 °C for 3.5 min and 1 cycle at 68 °C for 5 min followed 
by a cooling step at 4 °C. The amplified plasmid was then supplemented with 1 µl of 
Dpn I restriction enzyme (10 U/µl) at 37 °C for 1 hour to digest the parental plasmid. 
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Table. 3.1. Designed primers for mutants. 
Red indicates mutated bases 
 
 
 
 
 
 
 
 
 
 
Target Primer sequence 
Q77A Forward: 5' CATCGGCGTAATCGCAAAATTCGCCATTATGC 3' 
Reverse: 5' GCATAATGGCGAATTTTGCGATTACGCCGATG 3' 
T112V Forward: 5' CTGCTGCCCGGGCGGTGTAGCTTCCAATGTGATG 3' 
Reverse: 5' CATCACATTGGAAGCTACACCGCCCGGGCAGCAG 3' 
S114A Forward: 5' CCGGGCGGTACGGCTGCAAATGTGATGACCTATC 3' 
Reverse: 5' GATAGGTCATCACATTTGCAGCCGTACCGCCCGG 3' 
N115A Forward: 5' CGGTACGGCTTCCGCTGTGATGACCTATC 3' 
Reverse: 5' GATAGGTCATCACAGCGGAAGCCGTACCG 3' 
S128A Forward: 5' CAATGTGGCTTTGGCGGTTGCCGTTAC 3' 
Reverse: 5' GTAACGGCAACCGCCAAAGCCACATTG 3' 
T132A Forward: 5' GTCGGTTGCCGTTGCGTCTGTTTCCAC 3' 
Reverse: 5' GTGGAAACAGACGCAACGGCAACCGAC 3' 
I146C Forward: 5' CATTGCTGACTCCCGCCTGCTTCCTGATGCTTGCC 3' 
Reverse: 5' GGCAAGCATCAGGAAGCAGGCGGGAGTCAGCAATG 3' 
G267Q Forward: 5' GGTATGCAAAACTCGCAGCTGGCCGCCGCGCTTG 3' 
Reverse: 5' CAAGCGCGGCGGCCAGCTGCGAGTTTTGCATACC 3' 
A269C Forward: 5' CAAAACTCGGGCCTGTGCGCCGCGCTTGCCG 3' 
Reverse: 5' CGGCAAGCGCGGCGCACAGGCCCGAGTTTTG 3' 
H294Q Forward: 5' CAAAACTCGGGCCTGTGCGCCGCGCTTGCCG 3' 
Reverse: 5' CGGCAAGCGCGGCGCACAGGCCCGAGTTTTG 3' 
N295A Forward: 5' CAGCGTGTGGCAGAATATCTCCGGC 3' 
Reverse: 5' GCCGGAGATATTCTGCCACACGCTG 3' 
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3.1.2. Preparation of competent cells 
 Lemo21 competent cells were prepared as described below. A fresh colony of 
Lemo21 was selected from an LB agar plate to inoculate 100 ml of LB medium and 
the culture incubated at 37 °C with shaking at 220 rpm. Cells were grown until the 
O.D.600 reached around 0.5. Cells were transferred into two 50 ml falcon tubes and 
cooled on ice for 10 min. Cells were collected by centrifugation at 2,600 g at 4 °C for 
10min and gently resuspended with 10 ml of ice cold 0.1 M CaCl2 followed by a 
further 10 min incubation on ice. Cells were centrifuged again and the pellet was 
gently resuspended with 2 ml of ice cold 0.1 M CaCl2 and 20% glycerol. After 
incubation on ice for 10 min, cells were aliquoted into 50 µl samples and snap froze in 
liquid nitrogen. Frozen competent cells were stored at -80 °C.  
 
3.1.3. Transformation 
50 µl of Lemo21 competent cells were thawed on ice for 10 min before mixing 
with the plasmid. 1 µl of plasmid (200 ng/µl) was added to the competent cells and 
the mixture incubated on ice for 30 min followed by a heat shock at 40 °C for 1 min 
and then on ice for 2 min. 900 µl of LB media were added to the cells and the mixture 
incubated at 37 °C for 60 min while shaking at 900 rpm. 200 µl of incubated cell 
culture were then plated onto an LB agar plate supplemented with kanamycin (50 
µg/ml). 
 
 
 
 
 =?
3.1.4.  
Small scale expression screening of ASBTNM mutants 
 Colonies of transformed C43 cells or Lemo21 cells were picked from LB agar 
plates and inoculated into 10 ml of LB media supplemented with kanamycin (50 
μg/ml) in 50 ml falcon tubes. The cultures were incubated overnight at 37 °C with 
shaking at 220 rpm. 100 μl of this pre-culture were inoculated into 10 ml of each 
media, LB, TB and PASM5052 (Studier 2005), supplemented with kanamycin (50 
μg/ml) in 50 ml falcon tubes. For PASM5052 media different concentrations of 
rhamnose, 0 mM, 0.1 mM, 0.25 mM, 0.5 mM, 0.75 mM and 1.0 mM, were added. 
Cell cultures were incubated at 37 °C and 220 rpm until the O.D.600 reached 0.5 and 
induced by the addition of a final concentration of 0.2 mM or 0.4 mM IPTG. Induced 
cell cultures were incubated overnight at 25 °C or 30 °C and 220 rpm. 1 ml of the 
cells were transferred into 1.5 ml eppendorf tubes and centrifuged at 15,000 g for 1 
min and the supernatants were discarded. The cell pellets were resuspended with 100 
μl of 1 x PBS and transferred to 96 wells plate (black Nunc) and the fluorescence 
emission was measured using a SpectaMax plate reader (Molecular devices) with 
emission at 512 nm and excitation at 488 nm. Measured fluorescent counts were 
converted to the concentration of ASBTNM calculated from the fluorescent of pure 
GFP standard value as described in the formula below. 
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3.1.5. 
Fluorescence Size Exclusion Chromatography   
 The monodispersity of expressed fusion proteins was screened in crude 
dodecyl- β-D-maltopyranoside (DDM), decyl-β-D-maltopyranoside (DM), nonyl-β-
D- maltopyranoside (NM) or n-dodecyl-N,N-dimthylamine-N-oxide (LDAO) 
solubilised membranes by fluorescence size exclusion chromatography (FSEC) as 
described below. Crude membranes from 1 ml of E. coli cells cultures expressing 
ASBTNM mutants were centrifuged at 15,000 g for 1 min and the supernatants were 
discarded. Cell pellets were resuspended in buffer containing 20 mM Tris HCl pH 7.5 
and 150 mM NaCl and 1% or 2% of each detergents and incubated for 1 hour at 4°C 
to solubilise cell membranes. Solubilized membranes were collected by ultra 
centrifugation at 100,000 g for 45 min. The fluorescence of each supernatant was 
measured and adjusted to 3,000 with the resuspension buffer. The prepared 
supernatants were then directly applied to a size exclusion chromatography column 
equilibrated in a buffer containing detergent and the monodispersity of each mutant 
was measured with emission at 512 nm and excitation at 488 nm. 
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3.1.6.  
Large Scale Expression and Membrane Preparation 
Large scale expression of ASBTNM mutants 
 Colonies of transformed C43 cells or Lemo21 cells were picked from LB agar 
plates and inoculated into 10 ml LB media supplemented with kanamycine (50 µg/ml) 
in 50 ml falcon tubes. The cultures were incubated overnight at 37 °C and 220 rpm. 
20 ml of pre-culture were inoculated into 1 l of PASM5052 media (2% inoculation 
rate) supplemented with kanamycine (50 µg/ml) and 0.75 mM rhamnose. The cells 
were grown at 37 °C and 220 rpm until the O.D.600 reached 0.5 and induced by 
addition of 0.4 mM of IPTG. Induced cell cultures were incubated at 25 °C for 18 
hours and 220 rpm. The cells were harvested by centrifugation at 6,000 g for 10 min. 
Harvested cells were resuspended with 1 x PBS containing protease inhibitor cocktail 
and stored at -80°C or subjected to cell breakage immediately. 
 
Membrane preparation 
 The cells were diluted to 360 ml with 1 x PBS containing 1 mM of MgCl2 and 1 
mg of DNase. The cells were lysed at incremental pressures of 25 kpsi twice using a 
cell disruptor (Constant Systems) at 4 °C. Cell debris was removed by centrifugation 
at 10,000 rpm for 10 min at 4 °C and the supernatant was transferred to 
ultracentrifugation tubes. Membrane fractions were collected by ultracentrifugation at 
41,000 rpm for 1 hour at 4 °C. The supernatant was discarded and the membrane 
pellet was resuspended in 1 x PBS containing protease inhibitor cocktail using a glass 
homogenizer. The membrane suspension was flash frozen in liquid nitrogen and 
stored at -80°C or immediately purified. 
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3.1.7. Solubilisation and Purification 
Following purification steps were performed at 4°C and following the 
previously established protocol (Hu, 2011). Prepared membranes were solubilised in a 
buffer containing 1 x PBS, 150 mM NaCl, 10 mM imidazole and 1% DDM and 
stirred for 1 hour at 4°C. The suspension was cleared by ultracentrifugation at 
120,000 x g for 1 hour and unsolubilised membranes were removed. The solubilised 
membranes were mixed with 1 ml of Ni-NTA Superflow resin (Qiagen) (equilibrated 
with buffer containing 1 x PBS, 100 mM NaCl, 10% glycerol, 10 mM imidazole and 
0.1 % DDM) per 1 mg of GFP-His8 and incubated with stirring for 1 hour at 4°C. The 
slurry was loaded onto a glass Econo-Column (Bio-Rad) and washed with 10 column 
volumes (CVs) of buffer containing 1 x PBS, 150 mM NaCl, 20 mM imidazole and 
0.03% DDM. Bound material was washed for a further 10 CVs of buffer containing 
30 mM imidazole. The ASBTNM-GFP-His8 fusion protein was eluted in 2 CVs of the 
same buffer containing 250 mM imidazole. The eluted proteins were mixed with 
stoichiometric amounts of His8 tagged Tobacco Etch Virus (TEV) protease to separate 
ASBTNM mutants and GFP-His8. Samples were loaded into 30 kDa cut off dialysis 
membrane bag and incubated with stirring overnight in 3 l of buffer containing 20 
mM Tris-HCl pH 7.5, 150 mM NaCl and 0.03% DDM. Dialyzed samples were 
filtered using a 0.22 µm filter unit and passed through a 5 ml His-Trap column (GE 
Healthcare) pre-equilibrated with buffer containing 20 mM Tris HCl pH 7.5, 150 mM 
NaCl and 0.03% DDM. The following purification procedures were varied depending 
on whether the protein was to be used for a functional assay or for crystallization. 
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3.2. Biochemical methods 
3.2.1. Whole Cell Assay (Radio labeled substrate) 
E. coli C43 cells harbouring ASBTNM-GFP-His8 mutants were resuspended in 
uptake buffer consisting of 1 mM of CaCl2, 1 mM MgCl2, 10 mM Tris-HCl pH 7.5 
and 137 mM NaCl. Cells were incubated at 37 °C with uptake buffer containing 1-4 
mM taurocholic acid supplemented with 0.16 mM [3H]-taurocholate (PerkinElmer) 
for 5 min. Transport was terminated by the addition of ice-cold buffer containing 1 
mM CaCl2, 1 mM MgCl2, 10 mM Tris- HCl, pH 7.5, 137 mM NaCl and 1 mM 
taurocholate, and was followed immediately by centrifugation at 20,500 g for 120 
seconds. Cell pellets were washed two times in an equal volume of termination buffer 
and resuspended in 200 µl of the same buffer. The radioactivity corresponding to the 
internalized substrate was measured by scintillation counting.  
 
Sodium dependent uptake assay 
E. coli C43 cells harbouring ASBTNM–GFP–His8 mutants were incubated with 
1 µM taurocholic acid supplemented with 0.16 µM [3H]-taurocholic acid for 5 min in 
different NaCl concentrations 0, 100, 200 and 300 mM.  
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3.2.2. Proteoliposome transport assay  
(Radio labelled substrate) 
Sample preparation 
Purified WT ASBTNM and mutants were concentrated using a 50 kDa cutoff 
centrifugal concentrator (Millipore) to around 1 to 2 mg/ml, measured at absorbance 
of 280 nm using NanoDrop (Thermo Scientific), and flash frozen in liquid nitrogen in 
a 500 µl ependorf tube.  
 
Liposome preparation 
L-α-Phosphatidylcholine (from soybean/Sigma), SB lipids, was dissolved in 
the reconstitution buffer (10 mM MOPS pH 7.0, 5 mM MgCl2, 100 mM KCl) to a 
final concentration of 20 mg/ml and vortexed for 20 min at room temperature. Under 
these conditions the resuspended SB lipids form large and multilamellar vesicles 
(MLV). 1 ml of MLV were transferred to 1.5 ml eppendorf tubes and put on ice. 
Sonication was carried out with a titanium-tipped probe for 30 seconds at 40 % output 
(SONICS/Vibra cell) followed by 30 seconds rest and then repeated. During this 
treatment the liquid suspension turned into a slightly hazy transparent solution from a 
cloudy yellow color that indicated the formation of the single unilamellar vesicles 
(SUV). The titanium particles released from the tip were removed by centrifugation.  
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Reconstitution of protein into the liposomes 
1 ml of prepared SUV were mixed with 90 µl of 20 % sodium cholate at a 
final concentration of 40 mM. Cholate was used to reconstitute the membrane protein 
into liposomes by its solubilization ability with a low critical micellar concentration at 
9 – 15 mM. Then, 40 µl of 2 mg/ml purified ASBTNM were added to the destabilized 
liposome and sodium cholate mixture and this was incubated for 1 hour at room 
temperature. Reconstitution of ASBTNM into liposomes was accomplished by 
separating the sodium cholate from the liposome and ASBTNM mixture causing an 
exchange of sodium cholate from the surface of the ASBT transmembrane domain 
into the lipid bilayer of the liposomes. Since, the micellar molecular weight of sodium 
cholate (900 Da), is reasonably smaller than ASBTNM and liposomes, separation can 
be carried out by using PD-10 column (GE healthcare). 1 mL of incubated solution 
was applied onto a PD-10 column equilibrated with reconstitution buffer and the 
solution run though by gravity flow. 1.7 ml of reconstitution buffer was then added 
and the flowthrough discarded. 2.3 ml of reconstitution buffer were then added and 
the flowthrough collected in 15 ml falcon tubes. This contains separated ASBTNM 
reconstituted liposomes.  Prepared proteoliposomes were stored at 4 °C and could be 
kept for 2 days without any appreciable change in transport activity. 
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Transport assay 
Proteolipomes were then used for the taurocholic acid uptake assay. 
Radiolabeled taurocholic acid was used to monitor uptake ratio. To keep an 
electrostatic gradient across the lipid membrane, valinomycin, which is a potassium 
ion selective ionophore, was added to the proteoliposomes,. 150 µl of liposomes were 
transferred to 1.5 ml eppendorf tube and 5.2 µl of 4 M NaCl and 1 µl of 100 µM 
valinomycin were added to final concentration of 137 mM and 666 nM respectively.  
The reaction mixture was pre incubated at 37°C for 5 min before starting the uptake 
assay. The assay was started by the addition of 4 µM taurocholic acid supplemented 
with 0.666 µM [3H]-taurocholic acid (PerkinElmer), and incubated at 37°C for 5 min 
and 900 rpm. Transport was terminated by the addition of 150 µl ice-cold stop buffer 
containing 10 mM MOPS pH 7.0, 5 mM MgCl2, 100 mM KCl, 137 mM NaCl and 1 
mM taurocholic acid, and was followed immediately by application to a PD MiniTrap 
G-25 column (GE healthcare) to separate proteoliposomes from the taurocholic acid 
that had not been taken up. A further 700 µl of stop buffer was loaded and the 
flowthrough collected in a scintillation counting vial containing 2.5 ml of scintillation 
enhancing liquid (Scintillation plus / Packard biosciences). The radioactivity 
corresponding to the internalized substrate was measured by scintillation counting. 
The amount of taurocholic acid transported into the proteoliposomes were measured 
by the scintillation counter and values for each samples were subtracted from those of 
NapA as a blank control. NapA, Na+/H+ antiporter from Thermus thermophilus, was 
selected as a negative control for the assay. The reason for using NapA instead of the 
empty proteoliposome was to see the effect of another structurally homologous 
membrane transporter on the taurocholic acid uptake assay. Uptake ratios were taken 
as a percentage of WT ASBTNM, which was assigned to 100%.  
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3.2.3. Whole Cell Assay (Fluorescence substrate) 
The uptake of rhodamine was measured in E. coli C43 whole cells after the 
expression of WT ASBTNM-GFP-His8, Q77K, T112V, N295A, N295L, 
S114A+S128A, N115A+T132A, N115A+Q260A, Q260A+Q264A, Q77A+Q264A, 
S114A and N115A. As a negative control the empty vector expressing GFP -His8 was 
used. Time course assays were initiated by the addition of 5 µM rhodamine or 
rhodamine cholate to 100 µl of cells shaking at 900 rpm on a thermomixer comfort at 
37 °C. At specified time points the reaction was terminated by centrifugation at 
13,000 rpm for 60 seconds. Cells were washed in equal volumes of 1xPBS, 
resuspended in 100 µl of fresh 1xPBS and transferred to a 96-well black clear plate 
(Nunc). Rhodamine fluorescence was measured at 580 nm (excited at 530 nm).  The 
results were normalized for the amount of protein expressed using the GFP 
fluorescence measured at 510 nm (exc. 488 nm) using a spectrofluorometer.  
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3.3. Crystallization and structure determination 
3.3.1. ASBTNM E260A  
3.3.1.1. Crystallization 
Purified ASBTNM E260A was concentrated to 4-8 mg/ml using a 50 kDa 
cutoff centrifugal concentrator (Millipore) and loaded onto a Superdex 200 10/300 gel 
filtration column (GE Healthcare) equilibrated in 20 mM Tris-HCl, pH 7.5, 0.15 M 
NaCl, 1 mM taurocholic acid and 0.06% LDAO. The protein peak was collected and 
concentrated using a 100 kDa cut-off centrifugal concentrator (Millipore) to 30 mg/ml. 
Purified proteins were flash froze in liquid nitrogen and stored at -80°C or 
immediately used for crystallization. The sample was diluted with the buffer, 20 mM 
Tris HCl pH7.5, 150 mM NaCl, to 15 mg/ml. Taurocholic acid was added to the 
protein solution to a final concentration of 10 mM. Samples were centrifuged at 
15,000 g for 30 min at 4°C. Crystallisation trials were carried out with the Mosquito 
robot and the crystallization screens MemGold and Memsys&Memstart (Molecular 
Dimensions) and the same condition that gave crystals for the WT was also tried. The 
protein was mixed 1 µl : 1 µl with reservoir solution containing 50 mM sodium citrate 
pH 4.5, 70 mM NaCl, and 20-30% PEG 400.  24 wells hanging drop plate was 
incubated at 20 °C.  
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Dehydration of crystal 
Crystals were harvested using a MicroMesh loop (MiTegen) and directly 
mounted on the humidity controller HC1 (Sanchez-Weatherby et al. 2009). After 
removing extra precipitant solution from the loop using a small piece of Kimwipe, 
dehydration was carried out. Different humidity ranges from 40% to 80% and 
dehydration time from 1 min to 10 min were tested. Dehydrated crystals were frozen 
in liquid nitrogen and screened using synchrotron radiation at the Diamond Light 
Source. 
 
3.3.1.2. Data collection and analysis 
An X-ray diffraction data set was collected from beamline IO4 at the Diamond 
Light Source. Diffraction data were collected at 100 K using a beam size of 85 µm x 
85 µm at 100% intensity at a wavelength of 1.07 Å (11.58 keV) with an oscillation 
range of 0.5 °, 2.0 seconds per image and recorded on a CCD detector. The intensities 
from the collected data were integrated with XDS (Kabsch 2010) and scaled with 
SCALA in the CCP4 program suite (Winn et al. 2011). The initial model was 
prepared from the wild type structure, 3ZUY. Refinement, model building and 
electron-density map calculations were performed using Phenix refine (Afonine et al. 
2012) and COOT (Emsley and Cowtan 2004). Molprobity (Davis et al. 2007) was 
used to monitor and improve protein geometry. 
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3.3.2. ASBTNM Q77A 
3.3.2.1. Crystallization 
 Q77A mutant was crystallized by the lipidic cubic phase (LCP) method. As one 
of the advantages of LCP crystallization method is that detergent exchange is not 
necessary before the crystallization setup the last purification step using size 
exclusion chromatography was skipped and, after the reverse HisTrap steps, proteins 
were directly concentrated using a 100 kDa cutoff centrifugal concentrator (Millipore) 
to a final concentration of 25 mg/ml in the buffer containing 20 mM Tris HCl. 150 
mM NaCl, 10% glycerol and 0.03% DDM. 
 
LCP preparation 
 10 µl of 25 mg/ml of purified proteins were loaded into a gas-tight syringe (100 
µl volumes/Hamilton) using a Pipetman with 200 µl tips. The syringe was weighed 
and the weight of the empty syringe subtracted. The required amount of monoolein 
was calculated from the ratio of 2 : 3 (wt/wt) of protein and monoolein. The 
calculated amount of monoolein was added to another gas-tight syringe (250 µl 
volume/ Hamilton). The two syringes were connected by a coupler assemble. The 
LCP was mixed by pushing the mixture forwards and backwards between the two 
syringes until the mixture turned transparent, which indicates LCP formation. The 
prepared homogeneous LCP was then transferred to a 100 µl syringe and the needle 
assembly was connected to the syringe for dispensing. 
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Initial screening 
 For initial screening, MemGold and MemSys & Memstart crystallization 
screens were set up by a robot (Mosquito) at 20°C. 50 nl of LCP and 1000 nl of 
precipitant solution were dispensed onto a glass plate and sandwiched by a thin glass 
cover plate. These crystallization plates were incubated at 20°C. The plates were 
observed using a microscope with cross polarizers.  
 
Optimization of conditions 
 From an initial hit from the screening, optimized custom screening conditions 
were prepared. The E10 condition of MemSys&MemStart, 0.1 M NaCl, 0.1 M MES 
pH 6.5, 0.1 M LiSO4, 30% PEG400, was optimized as 0.1 M NaCl, 0.1 M MES pH 
5.5 – pH 7.0, 0 M – 0.15 M LiSO4, 24% - 32% PEG400. The LCP crystallization 
plates were set up with this custom screening by a robot system (Mosquito) at 20°C. 
50 nl of LCP and 1000 nl of precipitant solution were dispensed onto the glass plate 
and sandwiched by a thin glass cover plate. The crystallization plates were incubated 
at 20°C. The plates were observed using a microscope and tiny crystals were obvious 
when viewed between crossed polarizers. 
 
Harvesting LCP crystals from sandwich glass plates 
 The glass cover plate was cut using a glass-cuttting stone. The square-shaped 
cut glass was then removed using tweezers. As soon as possible after opening, 
crystals were observed between crossed polarizers and harvested using Micromount 
(Mitogen) loops. To reduce background scattering, crystals were harvested carefully 
with a minimum amount of LCP around the crystals. Harvested crystals were 
immediately cryocooled in liquid nitrogen. 
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3.3.2.2. Data collection and analysis 
An X-ray diffraction data set was collected at beamline I24 at the Diamond 
Light Source. Diffraction data were collected at 100 K using a beam size of 10 µm x 
10 µm 100% beam at a wavelength of 0.98 Å (12.68 keV) with an oscillation range of 
0.5 °, 0.1 seconds per images and a Pilatus3 6M detector. The intensities from the 
collected data were integrated with XDS and scaled with SCALA in the CCP4 
program suite. The structure was solved by molecular replacement with Phaser 
(McCoy et al. 2007). The initial model was prepared from the wild type structure, 
3ZUY. Refinement, model building and electron-density map calculations were 
performed using Phenix refine and COOT. Molprobity was used to monitor and 
improve protein geometry. 
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3.3.3. Wild type ASBTNM  
3.3.3.1 Crystallization 
Sample preparation 
Purified WT ASBTNM was concentrated to 4-8 mg/ml using a 50 kDa cutoff 
centrifugal concentrator (Millipore) and loaded onto a Superdex 200 10/300 gel 
filtration column (GE Healthcare) equilibrated in 20 mM Tris-HCl, pH 7.5, 0.15 M 
NaCl, 1 mM taurocholic acid and 0.06% LDAO. The protein peak was collected and 
concentrated using a 100 kDa cut-off centrifugal concentrator (Millipore) to 30 mg/ml. 
Purified proteins were flash frozen in liquid nitrogen and stored at -80°C or 
immediately used for crystallization. In addition to LDAO, various detergents were 
tried for crystallization trials including NM, OG, DM, cymal5 and MNG14.  
 
In complex with other bile acids 
10 mM of each bile acids, cholic acid, chenodeoxycholic acid, lithocholic acid, 
glycocholic acid and deoxycholic acid were mixed with crystallization samples and 
incubated for 30 min on ice and centrifuged at 15,000 g for 30 min at 4°C. Initial 
crystallization screening, MemGold and Memsys&Memstart (Molecular Dimensions), 
for ASBTNM in complex with bile acids was conducted using a robot system 
(Mosquito) with a protein and precipitant ratio of 100 nl : 100 nl. Crystallization 
plates were then sealed with a thin plastic seal and incubated at 20°C. 
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In complex with rhodamine 
Taurocholic acid and rhodamine were added to the protein solution to a final 
concentration of 1 mM and 10 mM respectively and incubated for 1 hour at 4°C. 
Samples were centrifuged at 15,000 g for 30 min at 4°C. Following the results from 
screening the sparse matrix screens the crystallization condition was optimized. The 
protein was mixed 1 µl : 1 µl with reservoir solution containing 50 mM sodium citrate 
pH 4.5, 70 mM NaCl, and 22-24% PEG 400. 24 wells hanging drop plate 
was incubated at 20 °C. 
 
Crystals were harvested and dehydrated in the same way as for E260A 
 
3.3.3.2. Data collection and analysis 
An X-ray diffraction data set was collected at beamline IO2 at the Diamond 
Light Source. Diffraction data were collected at 100 K using a beam size of 80 µm x 
83 µm 100% beam at a wavelength of 0.98 Å (12.66 keV) with an oscillation range of 
0.5 °, 2.0 seconds per images and recorded on a CCD detector. The intensities from 
the collected data were integrated with XDS (Kabsch 1993) and scaled with SCALA  
in the CCP4 program suite. The initial model was prepared from the wild type 
structure, 3ZUY. Refinement, model building and electron-density map calculations 
were performed using Phenix refine and COOT. Molprobity was used to monitor and 
improve protein geometry. 
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3.3.4. Homology modeling of human ASBT 
The homology model of human ASBT was prepared by MODELLER (Eswar 
et al. 2006) using ASBTNM WT, 3ZUY, and a multiple sequence alignment of 
ASBTNM (UniPort ID: Q9K0A9) to the human ASBT (UniPort ID: Q12908), human 
NTCP (UniPort ID: Q14973), SLC10A3 (UniPort ID: P09131), SLC10A4 (UniPort 
ID: Q96EP9), SLC10A5 (UniPort ID: Q5PT55), SLC10A6 (UniPort ID: Q3KNW5) 
and SLC10A7 (UniPort ID: Q0GE19) using ClustalW2 
(www.ebi.ac.uk/Tools/msa/clustalw2/). Evaluation of the model was checked by 
using MolProbity server.  
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3.4. Biophysical methods 
3.4.1. Circular Dichroism (CD) spectroscopy 
Sample preparation 
As imidazole interferes with CD spectroscopy, it was necessary to remove all 
traces of imidazole from the sample solution. In the purified sample imidazole still 
remained after dialysis at less than 2 mM in final concentration. Thus, buffer 
exchange was required before carrying out the CD experiment. Purified WT and 
mutants were concentrated to 0.5 ml using a 50 kDa cutoff centrifugal concentrator 
(Millipore) and loaded onto a Superdex 200 10/300 gel filtration column (GE 
Healthcare) equilibrated in 20 mM Tris-HCl, pH 7.5, 0.15 M NaCl, and 0.05% DDM. 
The SEC profile showed a single peak at a retention volume of 13 ml to 15ml. The 
fractions from this peak were collected and aliquoted into 0.5 ml eppendorf tubes 
without concentrating to avoid concentrating the DDM. Aliquoted samples were flash 
frozen in liquid nitrogen and stored at -80°C. Purified ASBTNM was defrosted and the 
concentration was adjusted to 30 µM with the CD buffer, 20 mM Tris-HCl, pH 7.5, 
0.15 M NaCl, and 0.05% DDM.  
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Near UV (240-340nm) 
 0.2 ml of samples were prepared with or without 200 µM taurocholic acid. Each 
sample was loaded into a 10 mm pathlength glass cells and mounted on beamline B23 
at Diamond Light Source. Absorption from the near UV wavelength (240-340nm) 
was measured at 20°C with 10 repeat scans.  
 
Far UV (170-260nm)  
 Taurocholic acid was added to 30 µM ASBTNM at concentrations of 30, 60, 150, 
600, 900, 1200 and 1800 µM respectively and incubated for 30 min at 4°C. 0.2 ml of 
each samples was loaded into a 10 mm pathlength glass cell and mounted on 
beamline B23 at Diamond Light Source. Absorption from the far UV wavelength 
(170-260nm) was measured at 20 °C with 20 repeat scans. CD data at 193 nm was 
plotted versus number of repeated scan to compare the differences in the unfolded 
protein ratio at each taurocholic acid concentration.  
 
The data were processed using CD Apps software and Origin software.  
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3.4.2. Isothermal Titration Calorimetry (ITC) 
Sample preparation 
Purified WT ASBTNM was concentrated to 4-8 mg/ml using a 50 kDa cutoff 
centrifugal concentrator (Millipore) and loaded onto a Superdex 200 10/300 gel 
filtration column (GE Healthcare) pre-equilibrated in the ITC buffer, 1xPBS pH 7.8, 
100 mM NaCl and 0.03% DDM. The SEC profile showed a single peak at a retention 
volume of 13 ml to 15ml. SDS PAGE showed that samples were highly pure without 
significant contamination of other proteins. The samples were concentrated to 15 
mg/ml using 50 kDa cutoff centrifugal concentrator and loaded into 10 kDa cutoff 
dialysis cassette, (Slide-A-Lyzer Dialysis Cassettes / Thermo scientific). The cassette 
was incubated with stirring overnight in 3 l of ITC buffer (see below). This dialysis 
buffer was used for ligand solution preparation. The sample was used for the ITC 
experiment directly. 
 
ITC experiment 
 The isothermal titration calorimetry experiments were performed at 25 °C on a 
MicroCal iTC200 (Malvern) at Oxford University. 200 µl of prepared 227 µM 
ASBTNM sample was degassed and loaded into the sample cell. 50 mM of taurocholic 
acid solution was prepared with ITC buffer, 1xPBS pH 7.8, 100 mM NaCl, 0.03% 
DDM and degassed. The degassed ligand solution was filled into the syringe unit. 
After a stable baseline had been achieved, the ligand was titrated into the stirred 
sample cell (1000 rpm). The injection sequence consisted of 2.5 µl injections during 
5.0 seconds at 180 seconds spacing up to 16 injections. As a control the dilution factor 
of the ligand in the ITC buffer was also measured. The titration data were processed 
using the Origin-ITC software package (Malvern). Heats of ligand dilution were 
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subtracted from the raw data. The subtracted heat changes for each titration was 
integrated and plotted versus the molecular ratio of ASBTNM and taurocholic acid. 
The data were processed using Origin iTC200 software. 
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3.4.3. Microscale Thermophoresis (MST) 
Sample preparation 
For the MST experiment at Imperial College London, the fluorescence of GFP 
was used to monitor the protein mobility. Purification procedures were finished by 
elution of Ni-NTA resin purification. 1 ml of sample was applied onto a PD-10 
column (GE-healthcare) equilibrated with the MST buffer and let pass through with 
gravity flow. Then 1.7 ml of the MST buffer were loaded and the flowthrough 
discarded. An additional 2.3 ml of MST buffer were then loaded the flow through 
collected in a15 ml falcon tube. This step was repeated to completely remove 
imidazole from the sample. The sample was aliquot into 0.5 ml eppendorf tubes and 
flash frozen in liquid nitrogen and stored at -80°C. 
 
MST experiment 
Unlabelled experiment: Purified ASBTNM was diluted to 500 nM with the MST buffer, 
20 mM Tris-HCl, 150 mM NaCl and 0.03% DDM, buffer and 10 µl of samples were 
aliquot into 16 1.5 ml eppendorf tubes. Taurocholic acid was added to the first tube at 
a final concentration of 2.5 mM then serial dilutions were prepared by transferring 10 
µl of samples to the following tubes. (Concentration range from 0.3 µM to 2.5 mM) 
Each sample were transferred to glass capillaries (Monolith standard capillaries from 
Nanotemper GmbH) and inserted into Monolith NT.LabelFree (Nanotemper GmbH) 
for MST-analysis.  
 
GFP labeled experiment: Purified ASBTNM GFP fusion protein was diluted to 50 nM 
with MST buffer and 10 µl of samples were aliquoted to 16 1.5 ml eppendorf tubes. 
Taurocholic acid was added to the first tube at final concentration of 20 mM then 
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serial dilutions were prepared by transferring 10 µl of samples to the following tubes. 
For example, taurocholic acid concentrations in each tube are 20 mM, 10 mM, 5 mM, 
2.5 mM, 1.25 mM, 0.63 mM, 0.31 mM, 0.16 mM, 78.13 µM, 39.06 µM, 19.53 µM, 
9.77 µM, 4.89 µM, 2.44 µM, 1.22 µM and 0.61 µM. Various taurocholic acid 
concentration ranges were also used. Each sample were transferred to the glass 
capillaries (Monolith standard capillaries from Nanotemper GmbH) and inserted into 
Monolith NT.115 (Nanotemper GmbH) for MST-analysis.  
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4. Results 
4.1. Expression and Purification 
4.1.1. Expression 
The following ASBTNM mutants were made, Q77K, Q77L, T112V, S114A, 
N115A, S128A, T132A, I146C, E260L, G267Q, A269C, H294Q, N295A, N295L, 
Q77A + E264A, A114A + S128A, A146C + A269C, N115A + T132A, Q260A + 
N115A and Q260A +Q264A. These mutations were prepared in addition to those 
made previously by Dr Hu (M48A, Q77A, K217E, E260A, Q264A, N265A, S291A 
and H294A). (Table. 4.1. lists the mutations and the reasons for making these 
mutations.) The expression conditions were screened to enable production of large 
amounts of protein for functional studies and crystallization. The best condition used 
Lemo21 cells in PASM5052 media (2% inoculation rate) supplemented with 0.75 
mM rhamnose. The cells were grown at 37 °C and 220 rpm until the O.D.600 reached 
0.5 and induced by the addition of 0.4 mM IPTG. The induced cells were incubated 
for 20 hours at 30 °C. All mutants expressed well in this condition with an average 
yield of 3.8 mg/ l /O.D.600 of expression. (Fig. 4.1. and Table. 4.2.) About two third of 
the mutants had similar expression levels to WT (4 mg / l / O.D 600), whereas the rest 
of the mutants expressed slightly less well than WT (2-3 mg / l / O.D 600). These 
expression levels gave suitable large amounts of homogeneous protein for 
crystallization studies.  
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Table. 4.1. ASBTNM mutants  
Binding target Position Aim 
Na1 S114A 
N115A 
S128A 
T132A 
E260A 
E260L 
S114A + S128A 
N115A + E260A 
N115A + T132A 
Is sodium 1 important for transport? 
Q77A 
Q77L 
Q264A 
Q77A + Q264A 
Is sodium 2 important for transport? Na2 
Q77K Can the positively charged lysine mimic the sodium ion? 
Na1 and Na2 E260A + Q264A What is the effect of preventing any sodium from binding? 
M48A 
N265A 
Both of these residues are highly conserved throughout the 
SLC10 family. They are both in the substrate binding pocket – 
what happens if they are mutated? 
N295A 
N295L 
This makes the only direct hydrogen bonding interaction to the 
taurocholic acid in the structure. In the human protein the 
equivalent residue is a leucine. 
Substrate 
H294A This interacts indirectly with the substrate in the structure 
through water molecules. It is reasonably conserved throughout 
the SLC10 family. 
S291A Differences in affinity of drugs binding to mouse and human 
proteins have been attributed to a mutation at this postion. 
T112V This residue is also near to taurocholic acid in the structure but 
its side chain was rather disordered. 
G267Q 
H294Q 
Both of these residues are highly conserved as glutamine 
throughout mammalian ASBT homolog. They are both in the 
substrate binding pocket – what happens if they are mutated? 
Other 
I146C 
A269C 
I146C + A269C 
From human ASBT model structure, these residues are both 
cysteine. 
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Table. 4.2. Expression screening of ASBTNM WT and mutants 
 O.D. 600 RFU mg/l mg / l / O.D 600 
S114A 5.2 87,000 22.6 4.3 
N115A 4.0 49,000 12.7 3.2 
S128A 5.6 102,000 26.4 4.7 
T132A 6.2 91,000 23.6 3.8 
E260A 4.8 87,000 22.6 4.7 
E260L 4.6 52,000 13.5 2.9 
Q77A 4.4 46,000 11.9 2.7 
Q77K 4.8 53,000 13.7 2.9 
Q77L 4.4 33,510 8.7 2.0 
Q264A 5.2 76,320 19.8 3.8 
Q77A+Q264A 4.6 46,750 12.1 2.6 
Q77A+E260A 5.6 86,800 22.5 4.0 
Q260A+Q264A 5.0 46,000 11.9 2.4 
M48A 5.0 48,000 12.4 2.5 
T112V 5.6 92,000 23.9 4.3 
N265A 5.8 82,000 21.3 3.7 
G267Q 6.0 100,000 25.9 4.3 
S291A 5.2 102,000 26.4 5.1 
H294A 5.0 93,000 24.1 4.8 
H294Q 5.4 91,000 23.6 4.4 
N295A 3.2 84,000 21.8 6.8 
I146C + A269C 5.4 91,000 23.6 4.4 
K217E 7.0 107,000 27.7 4.0 
WT 5.2 80,900 21.0 4.0 
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Fig. 4.1. Expression screening of ASBTNM WT and mutants 
Expression levels were monitored by measuring the GFP fluorescence count from the 
whole cell and converting this to the amount of ASBTNM.  The vertical scale 
represents the amount of ASBTNM (mg/l) over the O.D. 600 value. 
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4.1.2. FSEC 
 As shown by the results from the Fluorescence Size Exclusion Chromatography 
screen (FSEC), ASBTNM WT is monodisperse in DDM, DM, NM, NG, OG, LDAO, 
Cymal5 and Cymal6. (Fig. 4.2.a.) All the ASBTNM mutants had similar profiles. 
(Fig.4.2.b and c) This suggested that the mutants would be stable enough for 
purification and crystallization experiments as seen for WT. 
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Fig. 4.2. FSEC analysis of ASBTNM WT and mutants. 
WT and all the mutants show monodipersed peaks at the retention volume of 50 ml to 
55 ml. a. ASBTNM WT in 8 detergents, DDM, DM, NM, OG, LDAO, Cymal5, 
Cymal6 and NG. b. FSEC analysis in DDM for WT, Q77K, N295L, S114A+S128A, 
N115A+E260A, E260A+Q264A and Q264A+Q77A. c. FSEC analysis in DDM for 
WT, H294A, Q77K, C107A, N295L, S114A+S128A and N115A+T132A. 
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4.1.3. Purification 
ASBTNM WT and mutants were purified using established protocols by 
affinity purification using Ni-NTA resin following by TEV cleavage.  GFP was 
removed using a second HisTrap column after the protein had been cleaved. The 
purities of each of the proteins are shown in (Fig. 4.3.) 
 
 
 
 
 
 
Fig. 4.3. SDS-PAGE analysis of ASBTNM WT and mutants. 
S114A (lane 1), N115A (lane 2), S128A (lane 3), T132A (lane 4), E260A (lane 5), 
E260L (lane 6), Q77A (lane 7), Q77K (lane 8), Q77L (lane 9), Q264A (lane 10), 
Q77A+Q264A (lane 11), Q7A+E260A (lane 12), Q260A+Q264A (lane 13), M48A 
(lane 14), T112V (lane 15), N265A (lane 16), G267Q (lane 17), S291A (lane 18), 
H294A (lane 19), H294Q (lane 20), N295A (lane 21), I146C+A269C (lane 22), 
K217E (lane 23), WT (lane 24). The SDS-PAGE shows highly purified samples. In 
average 2-3 mg of purified proteins were obtained from 1 l of cell culture.  
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4.2. Biochemical methods 
4.2.1. Whole cell assay (Radio labelled substrate) 
From previously published data by Hu et al (2011), the activities of the wild 
type, Q77A, E260A, N265A and N295A were measured by a cell-based assay using a 
radio labeled substrate. To obtain more functional information, this assay was carried 
out for all the other mutants. However, initial experiments showed some 
inconsistency. At this point it was decided to turn to proteoliposomes to eliminate any 
unknown factors that could affect the uptake assay system, such as different 
expression levels or a wide variety of membrane proteins some of which might be 
capable to uptake/export bile acid across the membrane.	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4.2.2. Proteoliposome transport assay 
ASBTNM transports its substrate across the membrane from higher to lower 
concentration of sodium ions. Proteoliposomes were prepared with no sodium inside 
and a high sodium concentration outside. Thus, though ASBTNM is likely to be 
inserted into the lipid bilayer in different orientations the assay measures only 
substrate uptake into the proteoliposome. The results of the assay are shown in Fig. 
4.4. 
 
Control of the assay 
The assay was prepared with both positive and negative controls. Negative 
control: NapA was selected as a negative control for the assay. The assay result 
showed significantly lower uptake of taurocholic acid for NapA compared to 
ASBTNM WT. Positive control: From a homology model of human ASBT, C144 and 
C270 (I146 and A269 in ASBTNM) are both within disulphide bond formation of 
cysteines 105 and 106, which are equivalent to C107 and C108 in ASBTNM. Though 
in the reduced environment of the cell membrane it is unlikely that the residues would 
form a disulphide bond it was interesting to see whether a protein with these 
disulphide bridges could be made. This proved to be a good positive control in the 
assay as the mutations are not next to either the sodium ion or substrate binding sites. 
The proteoliposome transport assay shows almost the same activity for this mutants 
compared to WT.  
In general the assays were repeated three times using protein from the same 
purification batch. The reproducibility of the results from the transport assay with 
different batches of proteoliposomes was confirmed with WT and E260A, and 
reproducibility among different batches of purification samples was tested with WT, 
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Q77A, Q264A, E260A and I146C+A269C in two different experiments using slightly 
different protocols that were carried out in two separate visits to Sweden where the 
assays involving radioactivity were carried out. The experimental condition of the 2nd 
experiment was modified from the 1st experiment; the amount of proteoliposome for 
the assay was changed from 50 µl to 150 µl to enhance the signals. Among these 
samples, Q77A, E260A and I146C+A269C showed similar values, around 60%, 40% 
and 100% respectively, whereas Q264A varied slightly in the two experiments. (Fig. 
4.4.)  
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Fig. 4.4. Proteoliposome transport assay results. 
The amount of radio labeled taurocholic acid transporter for each mutant were 
converted to a percentage of the WT activity after the transport measured for the 
negative control NapA was subtracted. The grey column shows the WT activity, blue 
represents Na1 mutants, red represents Na2 mutants, white represents substrate 
binding mutants and light blue represents I146C+A269C (CC). (The double mutant 
involving both Na1 and Na2 binding sites E260A+Q264A is also in white.) a) The 1st 
experiment b) The 2nd experiment. 
 
 
Table. 4.3. Proteoliposome transport assay result (2nd experiment). 
 
 % Error 
WT 100.0 3.8 
T132A 79.5 3.7 
E260L 76.7 7.2 
N115A 64.9 4.0 
S128A 63.7 3.9 
S114A 56.0 3.0 
E260A 41.8 3.9 
Q77A 60.9 3.1 
Q264A 43.9 5.4 
Q77K 41.6 7.8 
Q77L 35.5 3.9 
E260A+Q264A 6.1 8.7 
Q77A+Q264A 0.0 3.3 
M48A 73.5 9.3 
G267Q 70.9 7.8 
S291A 57.7 9.4 
N265A 58.2 15.2 
T112V 44.7 3.0 
H294A 44.2 4.8 
N295A 0.0 7.6 
I146C+A269C 122.8 11.2 
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Na1 & Na2 mutants  
The Na1 mutants, T132A, E260L, N115A, S128A, S114A and E260A, have activities 
from 40% to 80% of the WT, whereas, the Na2 mutants, Q77A, Q264A, Q77K and 
Q77L have from 35% to 60% activity. (Fig. 4.4 and Table. 4.3.) Na1 mutants are 
reasonably active with more than 50% activity except E260A with 40%. Na2 mutants 
are less active than Na1 mutants with lower than 50% activity except Q77A with 60%. 
Notably, double mutants of E260A & Q264A and Q77A & Q264A completely lost 
uptake activity.  
 
Substrate mutants  
Mutants of substrate binding pocket residues, M48A, G267Q, S291A, N265A, T112V, 
H294A and N295A, appeared to have moderate activity from 45% to 75% except 
N295A, which showed no activity.  
 
Comparison with the previously published data 
For unknown reason, whole cell transport assay using radio labeled ligand did not 
work in this study that was well reproducible in the previous studies. It would due to 
the various factors in the living bacterial cell that cannot be controlled experimentally. 
Thus, instead of optimizing the experimental conditions to reproduce the proper 
condition, proteoliposome transport assay was investigated. Compared to the whole 
cell transport assay result from the previously published data, there are some 
inconsistencies between the transport activities of mutants. Q77A shows less than 
10% activity in the whole cell assay and 60% in the proteoliposome assay. N265A 
and N295A show around 20% activities in the whole cell and 60% and 0% activities 
in the proteoliposome assay. E260A shows the same activity in both assay systems. 
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There are some possibilities to answer this inconsistency, for example, whole cell 
assay involves the effect of other intrinsic transporters, proteoliposome assay is 
performed with purified proteins that would be more or less damaged during the 
process and proteoliposome assay was not repeated with different batch of purified 
samples. Further investigation is required to understand these differences. 
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4.2.3. Whole cell assay (Fluorescence substrate) 
Cell based assay 
Previously an uptake assay was carried out using radioactive substrate 
(tritiated taurocholic acid) and E.coli cells harbouring ASBTNM (Hu, 2011). As it was 
not possible to carry out radioactivity work at Diamond or the RCaH it was decided to 
investigate whether we could develop a fluorescence based assay using cholate linked 
to rhodamine. Rhodamine cholate gave a good signal in the assay compared to the 
negative control of cells expressing GFP. Thus, the signal of rhodamine cholate 
seemed to be related to the expression of ASBTNM. As only a small amount of 
rhodamine cholate was available, the assay was tried with rhodamine and it gave a 
good signal as well. Then, the assay was set up using rhodamine alone. However 
when the mutants were tested all mutants Q77K, T112V, N295A, N295L, S114A + 
S128A, N115A + T132A, N115A + Q260A, Q260A +Q264A, Q77A + Q264A, 
S114A and N115A show very similar values. (Fig. 4.5.)  
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Fig. 4.5. ASBTNM hourbouring E.coli whole cell and rhodamine assay. 
The E.coli cells were mixed with rhodamine and incubated at 37 °C. After 10 min 
(red column) and 20 min (green column) incubation, cells were separated from the 
rhodamine solution and washed with buffers. Molecular ratio between ASBTNM and 
rhodamine were calculated from the fluorescence of rhodamine and GFP. 
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In the initial experiments taurocholic acid was omitted from the stop buffer. In 
transport assays the addition of “cold” substrate in the stop buffer is often used to 
remove any fluorescence substrate that has bound to the protein rather than having 
been transported.  The addition of taurocholic acid to the stop buffer caused the 
fluorescence count to decrease. (Fig. 4.6.)  
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Fig. 4.6. Time course fluorescence based assay of ASBTNM in E.coli cells.  
a). Time course assay of ASBTNM and rhodamine. b). taurocholic acid was added at 5 
min incubation. Fluorescence of rhodamine significantly decreased after the addition 
of taurocholic acid. 
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This appears to be more consistent with binding rather than transport. As no 
difference could be observed in the binding of rhodamine between WT and mutants 
this assay was not thought to be appropriate to evaluate the mutants. However, from 
these results it appeared that rhodamine could bind to the extracellular side of 
ASBTNM. It was thought that it might be possible to use rhodamine as a ligand that 
could trap the conformation of ASBTNM in the outward facing state. 
 
 
	 
 
 
 
 
 
 
 
 
 
 
 
 
	   101	  
4.3. Crystallization and structure determination 
Crystallization of all the mutants, especially mutants in the sodium binding 
sites, was tried. Among those mutants, two structures were solved, Q77A and E260A. 
The proteoliposome transport assay result showed that both E260 and Q77 are 
important residues for the transport of taurocholic acid. Thus, these mutants were 
focused on. 
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4.3.1. E260A 
 The E260A mutation showed around 40% of WT transport activity, which was 
the lowest among the mutants in the Na1 binding site.  
 
4.3.1.1. Crystallization 
The E260A mutant crystallised in similar conditions to the WT. Crystals were 
grown at 20°C using the vapour diffusion method. Crystals appeared overnight and 
reached a maximum size after 3-4 days. (Fig. 4.7.) The sizes of the crystals were 
under 50 μm. It was found that dehydration of the crystal was necessary to improve 
the resolution of the diffraction data as seen for the WT crystals. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.7. Crystal of ASBTNM E260A. 
Crystals of ASBTNM E260A grown using the vapour diffusion method. The size of the 
crystal is around 50 mm. 
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4.3.1.2. Data Collection and Analysis 
These crystals had the same space group as the wild-type structure and 
diffracted to 3.0 Å.  (Fig. 4.8.) (Table. 4.4.) A data set was collected from a single 
crystal. The resolution limit of the data to use for further processing was determined 
to be 3.0 Å where the Correlation coefficient (CC50) was 0.52. The WT structure, 
3ZUY, was used as the initial model for the refinement and the Free R column was 
copied from the reflection file used for 3ZUY. Refinement parameters were screened 
to find the best parameters. 3 cycles of XYZ coordinate refinement was selected as a 
standard refinement parameter. In addition this the following options were tested 
individually: Individual B-factors, Group B-factor, Occupancies, TLS and using 
Reference model restraints to the previously solved WT structure (PDB code; 3ZUY). 
Among these options, Individual B-factors and Reference model restraints gave the 
best improvement as judged by the R-value and Rfree-value. It appeared that the best 
R-values were obtained after 4 cycles in Phenix and did not improve with further 
cycles. The main changes that were carried out during model building were as 
follows: Glutamate 260 was replaced with an alanine; the sodium ion was placed in 
the Na2 binding site bound to Q77 and Q264, whereas no electron-density was 
observed in the Na1 binding site. Two molecules of taurocholic acid were placed in 
the inward binding pocket and at the surface of the protein respectively in the same 
positions as for the WT structure. The final R-value was 23.2% and the Rfree-value 
was 29.5%. RMSD from ideal values were 0.012 (Bond length) and 1.788 (Bond 
angle). Other statistics including validation parameter can be seen in the table. 4.8.  
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Fig. 4.8. ASBTNM E260A X-ray diffraction image. 
The black circle indicates the diffraction limit at a resolution of 3.5 Å. The left box 
shows the spots at the highest resolution. 
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Table. 4.4. ASBTNM E260A data collection and refinement statistics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Values in parentheses are for the high resolution shells. 
a Rmerge = Σhkl ΣI |Ii(hkl)-<I(hkl)>|/Σhkl ΣI Ii(hkl), where Ii(hkl) is the intensity of an individual 
reflection and <I(hkl)> is the average intensity.  
 
Crystal E260A 
Wavelength (Å) 1.0703 
Beamline IO4 / DLS 
Oscillation range 0.5 ° 
Exposure time 2.0 s 
Transmission 100% 
Beam size 85  mm x 85 mm 
Space group P4
1
22 
Resolution (Å) 80.6 - 3.0 (3.2 - 3.0) 
CC50 0.99 (0.52) 
Cell dimensions (Å) a=b=72.5, c=161.1 
α=β=γ=90 
Number of measured reflections 74076 
Number of unique reflections 10024 
Completeness (%) 96.9 (82.6) 
Redundancy (%) 7.4 (3.1) 
I/σ(I) 13.0 (1.1) 
R
merge (%)
a 10.5 (71.8) 
Solvent content (%) 64 
  
Refinement  
Resolution (Å) 48.9 – 2.9 (3.1-2.9) 
Number of reflections 17681 
R-factor (%) 23.3 
R-free (%) 25.2 
R.m.s.d. from ideal values  
Bond lengths (Å) 0.005 
Bond angles (°) 1.15 
Ramachandran outliners (%) 0.0 
Ramachandran favored (%) 99.7 
Rotamer outliners (%) 0.4 
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The electron density showed that no large scale conformations had taken place 
relative to the WT structure, 3ZUY. The electron density at the Na1 binding site is 
consistent with an alanine residue instead of glutamate at position 260 (Fig. 4.9.a.) 
Negative difference density was observed when glutamate was refined at this position. 
(Fig. 4.9.b)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.9. ASBTNM E260A X-ray structure and electron densities. 
Electron density map of E260A. a). The electron density at the Na1 binding site. The 
2mFo-DFc map was calculated at 1.0 sigma (blue mesh). Glutamate 260 was 
substituted to alanine. b). 2mFo-DFc map (blue mesh) and mFo-DFc map (red mesh) 
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were calculated for glutamate 260 at 1.0 sigma and -3.0 sigma respectively. The 
negative mFo-DFc map can be seen around the side chain of glutamate 260. c). The 
electron density at the Na2 binding site in the presence of a sodium ion. The 2mFo-
DFc maps were calculated at 1.0 sigma and d) 2.0 sigma. The electron density for 
Na2 can be clearly observed. 
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Good electron density was seen in the Na2 binding site even when the maps 
were calculated at 2.0 sigma, (Fig. 4.9. c. and d.) whereas no electron density was 
observed for the sodium ion in the Na1 binding site. To prove this observation did not 
come from the low resolution of diffraction data, electron density maps for the wild-
type structure were calculated at the same resolution, 3.0 Å or lower, and compared 
with the maps from the E260A structure. (Fig. 4.10.) In these maps the electron 
density of Na1 in the wild type was clearly observed (even calculated at 4 Å, Fig. 
4.10.b).  
 
 
 
 
 
 
 
 
 
 
Fig. 4.10. The Na1 binding site of ASBTNM WT X-ray structure and electron 
densities. 
2mFo-DFc maps in the Na1 binding site of ASBTNM WT a). at 3.0 Å and b). at 4.0 Å.  
1.0 sigma maps were shown as blue mesh. Na1 was represented as blue sphere and 
electron density was clearly observed.  
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When the Na1 from the wild type structure was included in the E260A structure (Fig. 
4.11.) strong negative electron density was observed in this site.  
 
 
 
 
 
 
 
 
 
Fig. 4.11. The Na1 binding site of ASBTNM E260A X-ray structure and electron 
densities.  
2mFo-DFc map (1.0 sigma) and mFo-DFc map (-3.0 sigma) shown in the region of 
the Na1 binding site. Na1 (blue sphere) was superposed from 3ZUY WT structure and 
strong negative electron density was observed. 
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As a final check isomorphous difference Fo-Fo maps were calculated by using 
the structure factors of the WT and E260A with phases calculated using the WT 
structure. Differential maps at -3.0 sigma levels showed that clear negative electron 
density was observed at the positions of side chain of E260, Na1 and a water 
molecule that had been present in the WT structure. (Fig. 4.12.) Notably, no electron 
density was observed in this map at the Na2 position. From these data it seems that 
substitution of glutamate 260 with an alanine causes Na1 to be lost, or at least much 
more weakly bound, but has little effect on Na2.  
 
 
 
 
 
 
 
 
 
 
Fig. 4.12. Fo-Fo maps showing the differences between the WT and E260A 
structures. 
The red mesh shows the Fo-Fo map at –3.0 sigma and the green mesh at 3.0 sigma.  
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A comparison of the ASBTNM WT, 3ZUY, and the E260A structures gives an 
RMSD 0.24 based on the respective Cα atoms. No large conformational changes were 
observed in either the taurocholic acid or sodium ion binding sites. (Fig. 4.13.)  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.13. Superposition of WT (3ZUY) and E260A structures. 
The WT is shown as a grey ribbon and E260A as a green ribbon. The Na1 from WT is 
shown as a blue sphere and Na2 from both WT and E260A as red spheres 
(overlapped). a). Overview of superposed structures. b). Superposed Na1 binding site. 
The red circle indicates the position of the side chain of E260 in the WT structure. c). 
Superposed Na2 binding site. The Na2 from WT and E260A were assigned at almost 
the same position. d) Superposed taurocholic acid binding site. Minor changes were 
observed between the two molecules.  
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In summary, the mutation from glutamate to alanine at residue 260 causes Na1 to be 
lost from the binding site. Neither the mutation nor the loss of Na1 caused any 
conformational change with respect to the previously solved WT structure.  
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4.3.2. Q77A 
Q77 is one of the two residues that bind the Na2 through its side chain. The 
proteoliposome transport assay result showed that mutation of Q77 to alanine resulted 
in a protein with 60% activity compared to WT. Q264 is the only other residue that 
interacts with Na2 through its side-chain. Q264A expressed well and was 
monodisperse in FSEC. However, after solubilisation Q264A was not stable and 
precipitated.  
 
4.3.2.1. Crystallization 
The previous vapour diffusion crystallization condition that resulted in crystals 
of the WT and E260A proteins was tried for the Q77A mutant as well. However, no 
crystals were obtained, even when carrying out a broad screen, around this condition 
changing pH and PEG concentration. In addition no good crystals were found using 
sparse matrix screens. However, crystals were obtained using the LCP method. These 
crystals were grown at 20°C and reached a maximum size after 2-3 weeks. The best 
crystals were obtained from the optimized condition, 0.1 M NaCl, 0.1 M MES pH 5.5, 
0.1 M LiSO4 and 28% PEG400. (Fig. 4.14.) Although, the crystallization method was 
different from the WT and E260A crystals, this condition was similar to that of 
vapour diffusion method. The crystals did not grow bigger than 50 mm.  
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Fig. 4.14. Crystal of ASBTNM Q77A. 
Crystals of ASBTNM Q77A from LCP method. The size of the crystals is around 50 
μm. 
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4.3.2.2. Data Collection and Analysis 
The crystals were indexed as space group of P21. To collect a complete data 
set it was necessary to collect data from three different positions of a single crystal 
(Fig. 4.15. and Fig. 4.16.) This was done using the microfocus beamline.  
 
 
 
 
 
 
Fig. 4.15. Crystal of ASBTNM Q77A in a loop  
A Q77A crystal was fished using a MicroMesh loop and mounted on the microfocus 
beamline. The three pictures show the different positions of the crystal during the data 
collection. The red circle indicates the beam position. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 99>
 
 
 
 
 
 
 
 
 
 
Fig. 4.16. ASBTNM Q77A X-ray diffraction image. 
The black circle indicates the diffraction at a resolution of 3.2 Å. The left box shows 
the spots at the highest resolution. 
 
The resolution was cut at 3.2 Å where the CC50 was 0.53. The structure was 
solved by molecular replacement method using the wild type structure, 3ZUY, as the 
model. The structure contains 4 molecules in the asymmetric unit with a solvent 
content of 53%. This is much lower than the wild type crystals solved by vapour 
diffusion. The final R-value is 24.3 and the Rfree-value 30.4. RMSD from ideal values 
were 0.003Å (Bond length) and 0.800° (Bond angle). Other statistics including 
validation parameter can be seen in the Table. 4.5. 
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Table. 4.5. ASBTNM Q77A data collection and refinement statistics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Values in parentheses are for the high resolution shells. 
a Rmerge = Σhkl ΣI |Ii(hkl)-<I(hkl)>|/Σhkl ΣI Ii(hkl), where Ii(hkl) is the intensity of an individual 
reflection and <I(hkl)> is the average intensity.  
 
 
Crystal Q77A 
Wavelength (Å) 0.9778 
Beamline I24 / DLS 
Oscillation range 0.5 ° 
Exposure time 0.1 s 
Transmission 100% 
Beam size 10 mm x 10 mm 
Space group P1211 
Resolution (Å) 47.4 - 3.2 (3.4 - 3.2) 
CC50 0.99 (0.53) 
Cell dimensions (Å) a=85.0, b=88.8, c=96.1 
a=b=90, g=114.4 
Number of measured reflections 105782 
Number of unique reflections 21255 
Completeness (%) 98.4 (98.5) 
Redundancy (%) 5.0 (4.9) 
I/σ(I) 6.6 (1.1) 
R
merge (%)
a 22.4 (141.8) 
Solvent content (%) 53 
  
Refinement  
Resolution (Å) 47.4 – 3.2 (3.3-3.2) 
Number of reflections 35669 
R-factor (%) 24.3 
R-free (%) 30.4 
R.m.s.d. from ideal values  
Bond lengths (Å) 0.003 
Bond angles (°) 0.80 
Ramachandran outliners (%) 0.1 
Ramachandran favored (%) 97.9 
Rotamer outliners (%) 2.6 
	   118	  
Details of the refinement are described below. As for the E260A structure the 
refinement parameters were screened to find the best parameters. 3 cycles of XYZ 
coordinates refinement was selected as a standard refinement parameter. Among the 
options tested, Individual B-factors, TLS parameters and Reference model restraints 
improved the model. The best R-value and Rfree-value values were obtained when 
these four parameters were selected together. No improvement could be obtained after 
5 cycles. No large-scale conformational change was observed between the WT and 
the Q77A structure and the Q77A forms an inward facing conformation. In initial 
maps significant electron-density was not observed in either Na1 or Na2 binding sites. 
This was then examined more closely. The electron density maps showed clear 
negative density around Q77 if it was modeled as a glutamine as in the wild type 
structure rather than the alanine of the mutant. (Fig. 4.17.a.) When Na1 or Na2 were 
superposed from the 3ZUY structure and mFo-DFc maps were calculated at -3.0 
sigma. (Fig. 4.17.b and d) Strong negative electron densities were observed at the Na2 
binding site and the broad electron densities were observed at Na1.   
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Fig. 4.17. Electron density map of ASBTNM Q77A structure.  
2mFo-DFc map was calculated at 1.0 sigma and represented as blue mesh. mFo-DFc 
map was calculated at -3.0 sigma and represented as red mesh. a). The negative mFo-
DFc map can be seen around the side chain of glutamine 77. No significant electron 
density was observed for Na2. b). Na2 was obtained from superposed 3ZUY that 
represented negative electron density. c). Na1 binding site of Q77A showed that no 
significant electron density was observed for Na1. d). Na1 was obtained from 
superposed 3ZUY that represented the broad electron density. 
 
 

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The electron density of Na1 and Na2 in the WT structure were calculated at 
the same resolution, 3.2 Å or lower, and compared in the region of the sodium 
binding sites with the Q77A structure. (Fig. 4.18.) Even at the resolution, electron 
densities of Na1 and Na2 in wild type were clearly observed (even calculated at 4 Å), 
whereas in Q77A there was not a significant electron density at Na2 binding site. (Fig. 
4.17.)  
 
 
 
 
 
 
 
 
Fig. 4.18. The Na1 and Na2 binding sites of ASBTNM WT X-ray structure and 
electron densities. 
2mFo-DFc maps were calculated a). at 3.2 Å and 2.0 sigma and b). at 4.0 Å and 0.5 
sigma. Na1 and Na2 were represented as red and blue spheres respectively. Electron 
density maps for Na1 and Na2 were observed at both resolutions.  
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Because the space group of Q77A was different from the other structures, 
calculation of Fo-Fo maps between WT and Q77A structure factors was not 
applicable. In this structure, no significant electron density could be observed in either 
the Na1 or the Na2 binding sites, though some density could be observed in the Na1 
binding site. However, still it is possible that sodium ions may be bound in the 
binding site at lower occupancies and could not be observed due to the low resolution 
data. 
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A comparison of ASBTNM WT, 3ZUY, and Q77A structures showed an 
RMSD between Cα of 0.60. Overall the protein was in the same inward-facing 
conformation as the wild-type structure but some local changes were observed as 
described below.  
 
Na2 binding site of ASBTNM Q77A X-ray structure 
In the Na2 binding pocket, there are only two amino acid residues, Q77 and 
Q264 that directly bind to Na2 with their side chain. Though there is no clear 
conformational change of the main chain, substitution of Q77A or the absence of a 
sodium ion could affect the local structure around the pocket. (Fig. 4.19.d.) During 
refinement Gln264 was slightly moved toward the center of the Na2 binding site by 
around 1.0 Å. However due to the resolution of the Q77A structure, it is impossible to 
discuss this difference.  
 
Na1 binding site of ASBTNM Q77A X-ray structure 
Although the coordinates of all the residues corresponding to Na1 binding 
were similar to the wild type structure, density for a sodium ion was not clearly 
observed in the pocket. (Fig. 4.19.b) This may be due to the quality of the data but it 
could also be possible that the local conformational changes around the Na2 binding 
site caused by the Q77A substitution would affect the neighbouring Na1 binding site 
as well. This indirect conformational change might reduce the binding affinity of Na1.  
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Substrate binding site of ASBTNM Q77A X-ray structure 
While it was necessary to add taurocholic acid to the protein to obtain crystals 
of ASBTNM using vapour diffusion the crystal structure of Q77A was solved in the 
absence of taurocholic acid. Overall, between WT and Q77A no movements of the 
back-bone and side-chain of each residue were observed in the inward facing open 
pocket. (Fig. 4.19.c.) The conformation of the residues that bind to taurocholic acid in 
the WT structure do not change in the Q77A structure including T112, N265, H294 
and N195. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.19. Superposition of ASBTNM WT (3ZUY) and Q77A structure. 
WT is shown as a grey ribbon and Q77A as a light blue ribbon. Na1 from WT is 
shown as a blue sphere and Na2 from WT is shown as a red sphere. a). Overview of 
superposed structures. b). Superposed Na1 binding site. c). Superposed taurocholic 
acid binding site. d). Superposed Na2 binding site. Red circle indicated the side chain 
of Gln77 of WT structure. Gln264 is in a slightly different position in the two 
structures. 
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The space group of the Q77A crystal is different from the other ASBTNM 
structures, and the crystal packing is completely changed. Having two differently 
packing crystal structures can help us understand where the flexible regions of the 
protein are. In the WT and E260A structures a kink of TM1 was observed between 
Thr14 and Pro15 and the phosphate tail of taurocholic acid interacted with Lys13. The 
suspicion was that the kink in the helix was due to taurocholic acid binding. In the 
Q77A structure this kink still exists but the N-terminal part of the helix was tilted 
slightly from the WT structure toward the direction of the inward open pocket. (Fig. 
4.20.) This suggests that the kink is not caused by either crystallisation in detergent 
solution or the addition of taurocholic acid. In addition to the TM1, part of TM6 and 
TM7 (obvious differences are observed between Pro 173 and Leu192) slightly moved 
to be off from the core domain with the distance of 2.0 Å at the maximum.  
 
 
 
 
 
 
 
 
Fig. 4.20. Superposition of WT (3ZUY) and Q77A structures at TM1, TM6 and 
TM7. 
WT is shown as a grey ribbon and Q77A as a light blue ribbon. a. TM1 of Q77A 
tilted to inward facing pocket. b. TM6 and TM7 of Q77A moved away from the core 
domain. 
 
	   125	  
4.2.3. WT in complex with rhodamine 
In addition to the two mutant structures, WT crystallization was tried in order 
to solve the complex structure with another ligand than taurocholic acid. Rhodamine 
was selected as a candidate ligand to trap the WT in the outward facing conformation. 
As the whole cell binding assay result showed it could bind to ASBTNM but not be 
transported, it was assumed that rhodamine could bind to the extracellular side of 
ASBTNM.  
 
4.2.3.1. Crystallization  
Crystals were obtained from the vapour diffusion method using similar 
conditions for the previously solved WT structure. The crystals have the same pink 
colour of rhodamine. (Fig. 4.21.) 
 
 
 
 
 
 
 
 
 
Fig. 4.21. Crystal of ASBTNM WT in the presence of rhodamine. 
The pink rhodamine crystal mounted on the MicroMesh loop. The red square is 50 
mm x 50 mm. 
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4.3.3.2. Data Collection and Analysis 
An X-ray diffraction data set was collected at 3.5 Å. (Fig. 4.22.) The crystals 
had the same space group and similar cell dimensions as the wild type ASBTNM 
structure in complex with taurocholic acid. (3ZUY: P4122, a=b=73.4, c=162.5) The 
refinement protocol was similar to E260A giving a final R-value of 28.3% and Rfree-
value of 33.1% at 3.6Å. The RMSD from ideal values were 0.04Å (Bond length) and 
1.128° (Bond angle). There was no outlier in a Ramachandran plot and the number of 
residues in the favoured region was 99.7%. The number of rotamer outliers was 1.7%. 
The electron density showed that no large scale conformations had taken place 
relative to the 3ZUY structure. (Fig. 4.22.) No clear density was observed in the 
binding site. However, at this low resolution we cannot rule out that some rhodamine 
has weakly bound. 
 
 
 
 
 
 
 
 
 
 
Fig. 4.22. ASBTNM WT in complex with rhodamine X-ray diffraction. 
The black circle indicates the diffraction limit at a resolution of 3.5 Å. The left box 
shows the spots at the highest resolution. 
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Table. 4.6. ASBTNM WT data collection and refinement statistics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Values in parentheses are for the high resolution shells. 
a Rmerge = Σhkl ΣI |Ii(hkl)-<I(hkl)>|/Σhkl ΣI Ii(hkl), where Ii(hkl) is the intensity of an individual 
reflection and <I(hkl)> is the average intensity.  
 
 
Crystal WT-Rhodamine 
Wavelength (Å) 0.9795 
Beamline IO4 / DLS 
Oscillation range 0.5 ° 
Exposure time 2.0 s 
Transmission 100% 
Beam size 85  mm x 85 mm 
Space group P4
1
22 
Resolution (Å) 30.9 - 3.7 (3.9 - 3.7) 
CC50 0.99 (0.85) 
Cell dimensions (Å) a=b=74.82, c=162.92 
α=β=γ=90° 
Number of measured reflections 26677 
Number of unique reflections 5060 
Completeness (%) 94.1 (82.2) 
Redundancy (%) 5.3 (5.1) 
I/σ(I) 7.5 (1.8) 
R
merge (%)
a 10.2 (73.4) 
  
Refinement  
Resolution (Å)  30.8 – 3.7 (3.9-3.7) 
Number of reflections 5036 
R-factor (%) 28.31 
R-free (%) 33.07 
R.m.s.d. from ideal values  
Bond lengths (Å) 0.004 
Bond angles (°) 1.13 
Ramachandran outliners (%) 0.0 
Ramachandran favored (%) 99.7 
Rotamer outliners (%) 1.7 
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Fig. 4.23. Overview of ASBTNM WT structure and electron density map.  
ASBTNM was represented as ribbon style coloured with wheat. The 2mFo-DFc map 
was calculated at 1.0 sigma and shown as blue mesh. No significant electron density 
was observed in the binding pocket. 
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4.3.4. Homology modeling of human ASBT 
The sequence identity of ASBTNM to human ASBT is 26% and the residues 
forming the Na1 and Na2 binding sites are highly conserved. From the WT ASBTNM 
structure, 3ZUY, a homology model of human ASBT was prepared. (Fig. 4.24) The 
C-terminal amino acid residues of human ASBT, 313-348, were omitted from the 
model, which acts as a sorting signal for apical trafficking in rat (Sun et al. 2003). It is 
noteworthy that human ASBT has an extracellular N-terminus and a cytoplasmic C-
terminus (Hagenbuch and Meier 1994) and 9 transmembrane helices. Thus, TM1 in 
this homology model was actually exposed to the extracellular side.  Both the Na1 
binding site (S112, N114, S126, T130 and E261) and the Na2 binding site (Q75 and 
Q265) were formed as for WT ASBTNM. On the contrary to the conserved Na1 and 
Na2 binding sites, the inward facing pocket consists of different residues in the two 
species as described below. In WT ASBTNM, taurocholic acid bound to N295, 
possibly with Thr112 and through a water molecule to H294, followed by 
hydrophobic residues in the inward facing pocket. In human ASBT H294 is replaced 
by a glutamine, which is a relatively conservative change. Q297, on the other hand, is 
a leucine (L298). A leucine at this position is conserved in human ASBT and other 
members of the SLC10 family (NTCP and SOAT). (Fig. 4.25.) 	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Fig. 4.24. Superposed structures of human ASBT homology model and ASBTNM. 
a). Overview of superposed structures. Grey and wheat ribbons represented human 
ASBT model and ASBTNM respectively. b). Na1 binding sites. Na1 was shown as 
blue sphere from ASBTNM structure. c). Na2 binding sites. Na2 was shown as red 
sphere from ASBTNM structure. 
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Fig. 4.25. Superposed structures of human ASBT homology model and ASBTNM 
at taurocholic acid binding pocket. 
Grey and wheat ribbons represented human ASBT model and ASBTNM respectively. 
His297 and Leu298 of human ASBT were different from ASBTNM and highlighted as 
red characters.  
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4.4. Biophysical methods 
Two X-ray crystal structures of ASBTNM mutants were solved giving insight 
into how the sodium binding sites were maintained by the residues forming the 
respective sites. The contribution of each mutated residues was examined by the 
proteoliposome transport assay. In addition to these data, the detailed quantitative 
parameters of binding reaction would be important to characterise ASBTNM function. 
Because of the detergent properties of bile acids, functional analysis of the 
ASBTNM and bile acid reaction is extremely difficult and demands careful 
experimental approaches. The critical micellar concentrations of bile acids are lower 
than other detergents with around 3 - 10 mM. Thus, two physical events happen at the 
same time when bile acids are added to ASBTNM, binding and stabilization by a 
micellar effect. To measure the functional activity a detergent molecule is not suitable 
in the assay system except as a substrate molecule with a concentration at lower than 
the CMC value.  
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4.4.1. Circular dichroism (CD) 
CD spectroscopy was performed to evaluate the binding affinity of taurocholic 
acid to ASBTNM in detergent solution. Two different types of experiments were tried 
as described below.    
 
Near UV (250-330nm) region 
 At the near UV region, it is possible to monitor the tertiary structure of 
aromatic residues. In ASBTNM a phenylalanine, (Phe 15), is located 3.4 Å from the 
taurocholic acid. It was thought that if the rotamer of Phe15 was changed by binding 
taurocholic acid, differences of signals could be detected in the near UV region and 
the binding affinity could be obtained by titrating the concentration of taurocholic 
acids to ASBTNM. Unfortunately the spectra from ASBTNM were unaltered when 
taurocholic acid was added to the solution even at 200 µM. As it was not clear 
whether this is due to the lack of interaction between Phe15 and taurocholic acid or 
due to the low signal from the phenylalanine, Phe15 was substituted with a tryptophan. 
This resulted in noisy spectra, which were difficult to interpret. After this experiment, 
the structure of Q77A was solved without taurocholic acid. In the structure, the 
conformation of Phe15 was the same as that of the previously solved structure so it is 
perhaps unsurprising that no signal was observed.  
 
 
 
 
 
 
	   134	  
Far UV region (170-260 nm) 
 As a second step it was decided to use the Far UV region. This region of the 
spectrum gives information about the secondary structure of the protein. It is possible 
to determine the affinity of taurocholic acid to ASBTNM by titrating different 
concentrations of taurocholic acid and measure the stability of the protein as binding 
of taurocholic acid would help keep ASBTNM folded under the experiment. 
Differences in the stability were measured in the presence of taurocholic acid. As 
shown in Fig. 4.26.a, the effect of taurocholic acid on the stability of ASBTNM was 
apparent from the spectra. This gave conflicting results. From the result of the first 
measurement, compared to no taurocholic acid condition, the spectrum in the 
presence of 20 µM taurocholic acid showed ASBTNM to be more stable. When the 
experiment was carried out with various molar ratios of taurocholic acid to determine 
the KD value. ASBTNM was destabilized in most of the conditions. (Fig. 4.26.b.) 
Notably, the stabilities were not proportional to the concentration of taurocholic acid. 
Furthermore, reproducibility of the measurement with the fixed taurocholic acid 
concentration was not good either.  The detergent character of taurocholic acid could 
affect this result as taurocholic acid can be incorporated into the DDM micelle in the 
buffer (Luckey, 2008) and affect the stability of the protein.  
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Fig. 4.26. CD spectroscopy result in the far UV region. 
CD data at 193 nm were extracted from 10 repeated scans and converted to the 
relative values against the first scan. Percentages were plotted versus the number of 
repeated scans. Decline of the curves represent the unfolding of ASBTNM. a) Black 
square shows ASBTNM and red sphere shows ASBTNM in the presence of taurocholic 
acid at a 1:5 molor ratio. b). In the presence of various taurocholic acids molar ratios 
to ASBTNM. (red=1:1; cyan=1:5, blue=1:2; green=1:20; pink=1:30; olive=1:40; and 
grey=1:60) 
 
In summary SRCD spectroscopy detects differences of ASBTNM stability in 
the presence of taurocholic acid. However the experimental conditions to investigate 
the effect of taurocholic acid on ASBTNM could not be optimized. This may be due to 
several factors that could not be controlled including detergent concentration in the 
buffer and detergent aspect of taurocholic acid rather than as a ligand of ASBTNM.    
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4.4.2. Isothermal Titration Calorimetry (ITC) 
From the CD spectroscopy result it seemed difficult to obtain the binding 
affinity of taurocholic acids by measuring the stability of ASBTNM. Instead, ITC 
directly measures the reaction of the binding by detecting the heat changes in the 
system. Thus, ITC was performed to observe the binding reaction of taurocholic acid.  
To determine the KD value accurately from ITC, plotting a curve through the 
integrated heat changes of each titration against the molar ratio should give a 
sigmoidal line. The dilution factor of taurocholic acid was small enough that it did not 
affect the heat from the reaction between ASBTNM and taurocholic acid binding. (Fig. 
4.27.) The reaction stoichiometry and the KD are obtained from the centre of the 
isotherm. Once the ligand molecules in the ITC cell reach equilibrium, the following 
heat changes gradually decreased as the protein gets saturated. As shown in the ITC 
result the heat change did not reach saturation even when the molar ratio was 50. (Fig. 
4.28.)  
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Fig. 4.27. Result of ITC dataset of the baseline. 
Heat change versus time titration curve. Each peak represents an injection of 
taurocholic acid into the sample cells filled with the ITC buffer. Since the initial 
titration often give a noise signal, the initial peak was not used for the subtraction. 
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Fig. 4.28. Result of ITC dataset. 
Top). Heat change versus time titration curve. Each peak represents an injection of 
taurocholic acid into the sample cells filled with ASBTNM. The heat changes of the 
taurocholic acid dilution were subtracted. Bottom). Integrated heat changes for each 
injection versus molecular ratio of taurocholic acid and ASBTNM in the cell. 
 
Taurocholic	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From this result it is likely that taurocholic acid bound to ASBTNM in detergent 
buffer. However, the titration curve did not fit to the expected bile acid binding 
affinity deduced from the transport assays. It is possible that the experimental 
environment might interfere the measurement of binding reaction, for example, the 
detergent micelle, sample cells and stirring by syringe unit. 
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4.4.3. Microscale Thermophoresis (MST) 
The MST technique was demonstrated at RCaH. During this demonstration we 
measured the affinity of ASBTNM binding to taurocholate. The KD was estimated to 
be 31 µM, which is consistent with the expected KD from transport assays. (Fig. 4.29.) 
Further experiments were performed at Imperial College London. The machine used 
at RCaH monitored protein mobility by measuring intrinsic tryptophan fluorescence. 
On the other hand, the machine at Imperial College London measured GFP 
fluorescence rather than intrinsic fluorescence and required the protein to be 
conjugated to GFP.  
 
 
 
 
 
 
 
 
 
Fig. 4.29. Result of MST data  
MST result from the demonstration at RCaH. In the experiment ASBTNM was 500 nM, 
while taurocholic acid was titrated between 0.3 µM and 2.5 mM. Sigmoid plotting 
curve was plotted against the concentrations of taurocholic acid.  
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However, due to the limited access to the equipment and the lack of experience of use 
of this newly developed machine, no good results were obtained. The preliminary 
results of using the MST at RCaH suggest that it could be a useful technique for 
measuring the binding of substrates to ASBTNM in the future. 
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Discussion 
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5. Discussion 
5.1. Relationship between the structures and the 
function of ASBTNM 
In order to understand better the mechanism of taurocholic acid re-absorption 
by ASBT in the small intestine, functional and structural studies were carried out in 
this thesis. X-ray crystallography requires large amounts of purified protein, which 
has to be stable and homogeneous. Since, mammalian membrane proteins are poorly 
expressed heterologously, bacterial homologues are often used (Drew et al. 2006). 
The work in this thesis focused on a homologue of ASBT from Neisseria 
meningitides (ASBTNM). To interpret the data from the transport assays of the mutants 
it is desirable to see how the mutations affect the structure of the protein. The X-ray 
crystal structures of the mutants E260A and Q77A were solved where the mutated 
residues are in the Na1 and the Na2 binding sites respectively. In human ASBT, the 
residues corresponding to E260 and Q77 in ASBTNM are crucial for both taurocholic 
acid and sodium transport (Sun et al. 2006; Banerjee et al. 2008; Sabit et al. 2013). 
The E260A structure shows that Na1 is not present in the pocket or at least the 
occupancy is much lower than for the WT protein. No difference is observed at the 
Na2 binding site.  For the Q77A mutation the electron density in the both sodium ion 
binding sites is less than for WT. Neither of these mutations causes large changes to 
the protein structure and both structures still show the inward-facing state. 
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From the work described in the results the most reliable data to measure 
transport activity of mutants of ASBTNM was using proteoliposomes and a 
radiolabelled substrate. As the RCaH had no capabilities for carrying out radioactive 
measurements this assay was carried out in Sweden. Although, not all the mutants 
were repeated with different batches of purified samples, the structural and 
proteoliposome assay data are found to be correlated each other as described in below.  
 
Mutations of residues forming the Na1 binding site  
The results from the proteoliposome transport assay showed that E260A had 
the lowest transport activity of all the five alanine mutants of the residues forming the 
Na1 binding site. This result coincides with the fact that E260 is the only charged 
residue in the Na1 binding site. (Fig. 5.1.) The X-ray crystal structure of E260A 
revealed that sodium ion was not present in the Na1 binding site. These results 
suggest that E260 is necessary for the binding of Na1 and that Na1 is important for 
activity. Compared to E260A, E260L showed significantly higher transport activity, 
around 80% of WT. The purpose of this mutant was to block sodium ions binding at 
Na1 by occupying the space with a bulky leucine residue rather than alanine. Thus, it 
was expected that lower activity be obtained than with the other mutants at this site. It 
is possible that under the conditions of the assay the leucine allows the protein to take 
a conformation that is favourable for activity, though in the cell environment lack of 
sodium sensitivity may be detrimental. It is also possible that this measurement was 
an error. Although it was repeated twice this was with the same batch of 
proteoliposomes. 
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Fig. 5.1. Na1 and Na2 binding sites of ASBTNM  
Left). The side chains of Ser114, Asn115, Ser128, Thr132 and Glu260 interact with 
Na1. The backbone of Ser128 interacts with Na1. Glu260 is colored as red to 
represent the charged residue and the other residues are colored as white to represent 
no charged residues. Right). The side chains of Gln77 and Gln264 interact with Na2. 
The backbones of Val261, Glu260 and Met263 interact with Na2. Gln77 and Gln264 
are colored as red to represent the charged residue and the other residues are colored 
as white to represent no charged residues. 
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Mutations of residues forming the Na2 binding site  
 From the proteoliposome transport assay, both Q77A and Q264A showed 
significantly lower transport activities compared to WT, around 60% and 40%. When 
these two residues were both mutated to alanine, transport activity was completely 
lost. In the X-ray crystal structure of Q77A, electron density for sodium ions was not 
clearly observed at either the Na1 or the Na2 binding sites though there did appear to 
be density at both sites. The results indicate that substitution of Q77 might not result 
in complete loss of binding of Na2. Even without Q77 present, the other residues 
(Q264 and backbones of Met263, Val261 and Glu260) could keep the sodium ion in 
the binding site with a decreased affinity. (Fig. 5.1.) Also it is possible that the 
electron density in the binding site could come from water molecules binding with 
weak affinities. On the other hand, Q77 and the other residues could also support the 
transport activity of Q264A. As shown in the transport assay, double mutation of 
these residues resulted in loss of activity. Thus, at least one of Q77 and Q264 is 
necessary for transport. In the same way as for E260L, Q77L was prepared to see 
whether this would block the sodium ion from binding at Na2 or not. The result 
shows that Q77L has significantly lower activity than Q77A. This result suggests that 
the substitution of Q77 to leucine rather than alanine would not only decrease the 
affinity of Na2 but also prevent it binding. On the other hand, the aim of the Q77K 
mutant was to replace Na2 with a positively charged residue. In the sodium proton 
antiporters, which are structurally homologous to ASBTNM a lysine is situated at the 
same place as the sodium ion (Lee et al. 2013,	   Fig,	  5.2.). In the transport assay this 
mutant showed around half the activity of WT, even lower than Q77A. Although this 
result supports the importance of Na2, further experiments are required to confirm 
whether Q77K could actually mimic the sodium ion in the binding site or not. 
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Fig. 5.2. Superposed Na2 binding site of ASBTNM to NhaA.  
Structural comparison of Na2 of ASBTNM and Lys300 of NhaA. Grey and wheat 
ribbons represented NhaA and ASBTNM respectively. The Na2 in ASBTNM is 
depicted as purple sphere and Lys300 in NhaA as stick model. TM4, TM8 and TM9 
of ASBTNM were superposed on TM4, TM10 and TM11 of NhaA. Na2 of ASBTNM is 
situated in the nitrogen atom position of Lys300 of NhaA.  
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Mutations in both sodium ion binding sites  
From the transport assay of residues in both the sodium ion binding sites, it 
seems that both ions contribute to transport of taurocholic acid. On average mutants 
of the Na2 binding site show a larger decrease in activity than the mutants at the Na1 
binding site. The double mutation of residues in both the Na1 and Na2 sites, E260A 
and Q264A, results in complete loss of transport activity. Although both Na1 and Na2 
might have some binding affinities without those residues, when they are combined it 
would lead to loss of transport activity. 
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Substrate specificity  
Seven amino acid residues located in the substrate binding pocket of the 
inward-facing structure were substituted to alanine or other amino acids to investigate 
their role in transport. (Fig. 5.4.) Among these residues M48, N265 and S291 are 
conserved in human ASBT and alanine mutants show around 60% to 70% activity 
compared to WT. Though these residues do not directly interact with taurocholic acid 
in the structure, they are located in the possible transport pathway between the panel 
domain and the core domain. The decreased activity of these residues could support 
that taurocholic acid is transported through between the two domains. T112 is also 
conserved in human ASBT and close to the taurocholic acid but it could not be 
assigned well in the X-ray crystal structure (Hu, 2011). However, compared to M48, 
N265 and S291, alanine substitution at this position shows lower transport activity. 
T112 could have an ability to bind to taurocholic acid. H294 interacts with 
taurocholic acid through a water molecule and alanine substitution shows around 45% 
activity. In human ASBT the equivalent residue is Q297. Similar to T112, H294 could 
also have an essential role for the transport of taurocholic acid. G267 is one of the two 
non-conserved residues in human ASBT and humanized mutant G267Q shows around 
70% activity. In spite of the difference between alanine and glutamine, G267Q still 
possesses reasonably high activity among the other mutant. Since the substrate 
binding pockets are not well conserved, this substitution could slightly decrease the 
activity in ASBTNM. The transport assay shows that N295 is crucial for activity with 
completely loss of uptake of taurocholic acid when it is replaced by an alanine.  This 
result is consistent with the structural information that N295 is the only residue that 
directly binds to taurocholic acid through its side chain. On the other hand, as 
mentioned in the results chapter, the whole cell transport assay result from the 
 9=9
previously published data shows N295A as around 20 % activity. Though the exact 
activity is not clear from this study, N295 is still the one of the important residue for 
the transport activity. 
Although ASBTNM showed similar transport activity to human ASBT, there 
were some non-conserved residues around the inward facing pocket. N295 was one of 
those unique residues. Detailed comparisons between human and bacterial ASBTs are 
described later.  
 
 
 
 
 
 
 
 
 
Fig. 5.3. Inward facing pocket in ASBTNM (3ZUY) 
a. Inward facing open pocket. The inward facing pocket consists of hydrophobic 
residues, Phe15, Leu47 Ala113, Val116, Met117, Leu120, Pro196, Ser199, Val200 
and Ile203.   b. Taurocholic acid binding residues in ASBTNM inward facing open 
pocket. Thr112 and Asn295 form hydrogen bonding with taurocholic acid. Both 
Asn265 and His294 interact with taurocholic acid via water molecules. 
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Fig. 5.4. The inward facing pocket of ASBTNM (3ZUY) for proteoliposome 
transport assay 
The residues for proteoliposome transport assay are highlighted as stick model. Two 
red spheres represent water molecules. 
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5.2. X-ray crystal structure of ASBT from 
Yersinia frederiksenii. 
While this thesis was being written up, the structure of another bacterial 
homologue of ASBT from Yersinia frederiksenii (ASBTYf) was solved (Zhou et al. 
2014). The sequence identity of ASBTYf to ASBTNM is 43% and most of the 
functionally important residues are highly conserved. (Fig. 5.5.) ASBTYf transports 
taurocholic acid with a similar KM value to ASBTNM (around 50 µM). For the ASBTYf 
sodium ions were shown to be necessary for the transport of taurocholic acid, in 
which the stoichiometry of sodium ions to taurocholic acid is 2:1. The structure was 
solved of the protein in both the inward facing and the outward facing conformation 
by the LCP crystallization method to 1.95Å and 2.5Å respectively. (Fig. 5.6.) In spite 
of the high identities, some remarkable differences exist among them.  
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Fig. 5.5. Schematic diagram of the topology ASBTYf. 
Cartoon representation of ASBTYf oriented with the periplasm on top. The helices are 
coloured to depict TMs 1 to 10 and grouped by domain. Pink and light blue trapezoids 
indicate inverted repeat motifs, TM1 to 5 and TM6 to10 are psudo-symmetry related 
each other. Respective pink and light blue motifs form core domain and panel domain.   
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Fig. 5.6. X-ray crystal structures of ASBTYf. 
The colours of helices are the same as Fig. 5.5. Overview structures of a). inward 
facing conformation (4N7W) and b). outward facing conformation (4N7X). The 
substrate binding pockets were formed between the panel domain and core domain in 
both inward and outward facing conformations. Supposed Na1 binding sites of 
ASBTYf in c) inward facing conformation and d). outward facing conformation. The 
dashed circle indicates the superposed Na1 from ASBTNM WT structure. Ser126 was 
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highlighted as red label that was differ from Thr in ASBTNM. The first turn of TM4b 
was unwound in the inward facing conformation. Supposed Na2 binding sites of 
ASBTYf in e). inward facing conformation and f). outward facing conformation. 
Dashed circle indicated the superposed Na2 from ASBTNM WT structure. His71 was 
highlighted as red label that was differ from Gln in ASBTNM. 
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Fig. 5.7. Sequence alignment of ASBTYf to ASBTNM, human ASBT and human 
NTCP. 
Sequence alignment of ASBTyf (UniPort ID: C4ST46) to ASBTNM (UniPort ID: 
Q9K0A9), human ASBT (UniPort ID: Q12908) and human NTCP (UniPort ID: 
Q14973) using ClustalW2 (www.ebi.ac.uk/Tools/msa/clustalw2/) and figure 
preparation in JalView. (Waterhouse et al. 2009) The sequence identity of ASBTYf to 
ASBTNM, human ASBT and human NTCP were 43%, 24% and 25% respectively. 
The coloured bars depicted the location of the transmembrane α-helices in ASBTNM 
and the colours of helices were the same as Fig. 5.5. Residues forming Na1 and Na2 
binding sites were highlighted as blue and red boxes and inward facing open pocket 
as pink.   
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The superposed inward facing conformation structures of ASBTNM (3ZUY), 
and ASBTYf, (4N7W), showed that both the panel domain and the core domain highly 
resemble each other except for the kinked TM1 in ASBTNM. (Fig. 5.8.) The inward 
facing conformation of ASBTYf was solved without either taurocholate or sodium 
ions bound in the pocket (PDB code; 4N7W). Instead of taurocholic acid, a citrate 
molecule was bound in the inward facing pocket, which is contained in the 
crystallization condition. The amino acid residues in the Na1 and Na2 binding sites of 
ASBTYf are highly conserved. The only substitutions are conservative: T132 in 
ASBTNM is a serine in ASBTYf and Q77 in ASBTNM is a histidine in ASBTYf. A 
comparison of the sodium binding sites in ASBTNM and ASBTYf showed that the first 
turn of TM4b is unwound in ASBTYf and has moved away from the crossover region 
between TM4 and TM9. As a result, Ser108 and Asn109 (Ser114 and Asn115 in 
ASBTNM) located in the TM4b are not in position to bind the sodium ion in the Na1 
binding site. (Fig. 5.8) It is not clear why sodium ions were not observed in the 
inward facing ASBTYf structure. The crystallization conditions were similar to those 
for ASBTNM (0.1 M Na Citrate and 0.1 M NaCl) and in fact contained slightly higher 
concentrations of sodium ions.  In this structure there was a citrate bound in the active 
site. Interestingly, the tilt of TM4b exposes the Na1 binding site to the intracellular 
side and this is a possible sodium transport pathway. It can be assumed that the 
ASBTNM inward facing structure represents the intermediate state just before 
releasing substrate and/or sodium ions into the cytoplasm. As the conditions under 
which the crystals were grown are different to those in the cell, in which sodium 
concentration gradient between the cell membrane was absent, releasing sodium ion 
from ASBTNM sodium binding site to cytoplasm could not happen.  
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Fig. 5.8. Superposed inward facing conformations of ASBTNM and ASBTYf 
Grey and wheat ribbons represent ASBTYf and ASBTNM respectively. Red and blue 
spheres represent Na2 and Na1 from the ASBTNM structure. a). Overview of 
superposed structures. Red circle indicates the taurocholate binding site. b). Na1 
binding site. c). Na2 binding site. No significant conformational changes were 
observed between the two structures. 
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The outward-facing structure of ASBTYf was obtained with the equivalent 
mutation to E260A that was made for ASBTNM (PDB code; 4N7X). They obtained the 
outward facing conformation of ASBTYf in crystallisation conditions that did not 
contain sodium ions in the crystallisation buffers (39% PEG400, 0.1 M Tris-HCl pH 
8.5, 0.1 M KCl and 10 mM MnCl2), though no attempt was made to remove the trace 
sodium ions.  The pH value of 8.5 was higher than that of other ASBTNM and inward 
facing ASBTYf structures. For ASBTNM no diffracting crystals were obtained under 
such conditions. The different results would come from various reasons; the 
crystallization methods were LCP in ASBTYf and vapour diffusion in ASBTNM, 
absence of sodium ion and taurocholic acid in the crystallization condition of ASBTYf 
structure (the addition of taurocholate was necessary to obtain good crystals of 
ASBTNM using vapour diffusion, in which taurocholic acid binds both in the binding 
pocket and the crystallisation interface), and, importantly, these are different proteins. 
As for the inward facing structure, there were no substrate and sodium ions in the 
ASBTYf outward facing structure. When the panel domain and the core domain were 
superposed to that of the inward facing conformation structure individually, each 
domain aligned well without significant conformational changes. When the core 
domains of each conformation are superposed, a large movement of the panel domain 
can be observed, in which the panel domain relatively “rotates” along the core domain. 
This rigid body motion of the panel domain and the core domain could explain the 
conformational change from inward facing to outward facing conformation of 
ASBTYf. From the inward facing conformation, the panel domain moves relative to 
the core domain and the outward facing pocket is formed by the dissociation of the 
core domain, TM9b, and the panel domain (TM2 and TM7). (Fig. 5.9.) Due to their 
highly similar sequence identity and homologous structures, it is likely that this 
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conformational change mechanism could be also applied for ASBTNM as well. In the 
ASBTNM structures, the small differences could be observed between the structure of 
the Q77A mutant and the WT at TM1, TM6 and TM7. Since the displaced TMs are 
distant from the substituted residue, it is likely that this comes from the different 
packing between the crystals formed from LCP or vapour diffusion methods and/or 
the absence of taurocholic acid. From this observation, this movement would imply 
the flexibility of the panel domain in the inward facing conformation. It is assumed 
that the flexibility of the panel domain might be important for taurocholic acid 
transport moving against the core domain.   
 
 
 
 
 
 
 
 
 
 
Fig. 5.9. Conformational change between inward and outward facing structures 
of ASBTYf.  
Grey and wheat rods represented outward and inward facing structures of ASBTYf. 
Rigid body movement of TM4 and TM9 against TM2 and TM7 were observed. 
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To help to understand the outward facing conformation of WT ASBTNM, the 
core domain of ASBTNM and ASBTYf were superposed. (Fig. 5.10.) Overall, both 
TM4 and TM9 were well aligned in the inward facing and the outward facing 
conformation. However there were some minor differences that unlike the inward 
facing conformation of ASBTYf, the first turn of TM4b in the structure of ASBTNM 
forms an α-helix. One interpretation from this comparison is that TM4 and TM9 
change their conformation, by unwinding TM4b, to release sodium ions into the cells 
with the sodium gradient as a driving force. This would mean that the E260A and 
E254A structures may not be representative of the protein with no sodium ion at Na1. 
The other possibility is that the citrate ion at the binding site of the inward-facing 
ASBTYf causes some conformational changes of the helices.  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.10. Superposed structures of ASBTNM and ASBTYf at the core domain. 
a). Inward facing conformations were well aligned excepting Na1 binding sites. b). 
There were no significant differences among outward facing conformations. 
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The authors of the ASBTYf paper used a scintillation proximity assay (Miller 
et al.) assay to measure the binding affinity of taurocholic acid to ASBTYf. This 
method observes the binding of radio labelled taurocholic acid to purified ASBTYf in 
detergent solution. They mutated a number of residues in the protein and measure 
binding. Five of the mutated residues were the same as the ASBTNM mutants, T106V, 
S283A, N259V, N287V and H286A (T112A, S291A, N265A, N295A and H294A in 
ASBTNM), though three of them were to valine rather than alanine. (Fig. 5.11.) 
Among these mutants, T106V, N259V, S283A and H286A support the activities seen 
for ASBTNM. The outlier is N295A/N287V. For ASBTNM no transport was observed, 
while the binding to ASBTYF was around 80%. There can be a number of reasons for 
this difference. 1) These values were obtained from different methods. One measures 
binding the other transport. 2) The substituted residues were not the same, and this 
has an affect on the conformation of the protein (valine for ASBTYF and alanine for 
ASBTNM). 3) The proteins are not the same and the binding mode differs between the 
two. 4) The proteoliposome transport assay was done on a single batch of purified 
sample, which had lost activity. However, this mutant also showed low activity in the 
whole cell assay previously carried out (Hu, 2011) and makes sense with the binding 
mode seen in the crystal structure. Further work is required to resolve this issue.  
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Fig. 5.11. Superposed structures of ASBTNM and ASBTYf at the taurocholic acid 
binding site. 
Grey ribbon and wheat ribbon represent ASBTYf and ASBTNM respectively. Red and 
blue spheres represent Na2 and Na1 and wheat stick represents taurocholic acid from 
the ASBTNM structure. Sitck residues represent mutated residues of ASBTyf. 
 
 
 
 
 
 

	   165	  
5.3. Human ASBT homology model  
Human ASBT has been extensively studied by mutagenesis coupled with cell-
based transport assays. Alanine substitutions at Q75 (Q77; equivalent residues in 
ASBTNM are shown in brackets) and S112 (S114) were reported to cause loss of 
transport activity (Sabit et al. 2013; Saeki et al. 2013). Cysteine substitutions at T130 
(T132), E261 (E260) and Q265 (Q264) result in less than 10% activity (Banerjee et al. 
2008; Sabit et al. 2013). Though the absolute percentages differ, the loss of activity is 
consistent with the results seen for ASBTNM. The difference in numbers may be due 
to the proteins being different or due to the different sensitivity of the assays. The, 
homology model from ASBTNM therefore can help us understand the human ASBT 
mechanism.   
From the comparison between human ASBT and bacterial ASBTs, both the 
Na1 and the Na2 binding sites are likely to be very similar. (Fig. 5.12.) It is also likely 
that human ASBT will change from the outward to the inward-facing states by a rigid 
body motion of the core and the panel domains followed by the local change of 
discontinuous TM4 and TM9 helices for the transport of sodium ion. The exact 
movements are likely to differ especially since TM1 is not present in human ASBT. 
However, still the mechanism of taurocholic acid transport is not clear due to the low 
similarity of the mammalian and bacterial species in the substrate binding pocket. 
From the proteoliposome transport assay, the alanine mutation at N295 had no 
transport activity, as discussed above. As taurocholic acid is not a natural substrate of 
ASBTNM in the bacterial cell as described in the introduction, this asparagine might be 
related to the original substrate specificity of ASBTNM. More structural information of 
other conformations, such as the occluded state, of ASBT is necessary to understand 
the precise bile acid transport mechanism.   
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Fig. 5.12. Superposed structures of human ASBT homology model and ASBTNM. 
a). Overview of superposed structures. Grey and wheat ribbons represented human 
ASBT model and ASBTNM respectively. b). Grey and wheat ribbons represented 
human ASBT model and ASBTNM respectively. His297 and Leu298 of human ASBT 
were different from ASBTNM and highlighted as red characters. c). Na1 binding sites. 
Na1 was shown as blue sphere from ASBTNM structure. d). Na2 binding sites. Na2 
was shown as red sphere from ASBTNM structure. 
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CHAPTER 6 
 
Summary 
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6. Summary 
The X-ray crystal structure of a bacterial homologue of ASBT, ASBTNM, was 
previously solved at 2.2Å In this thesis, in order to understand the precise mechanism 
of ASBT transport, both structural and functional studies were done. The residues 
forming the Na1 binding site, the Na2 binding site and the inward facing open pocket 
were mutated to alanine or other amino acid residues to see the effect on the transport 
activity of ASBTNM. These mutants were expressed in the E.coli, purified and 
reconstituted to the liposome and transport activities were measured by the radio 
labeled taurocholic acid uptake. The result shows the equivalent contributions of both 
Na1 and Na2 binding sites for the transport in which alanine substituted mutants 
decreased the activities. The inward facing open pocket mutants also decrease the 
transport activities. In particular N295A completely blocks taurocholic acid uptake 
that suggests the importance of N295 on ASBTNM transport activity. However, this is 
not conserved in the human ASBT. It should also be noted that the proteoliposome 
transport assay measurements in this study were not extensively repeated with 
different batches of protein.  
 E260 and Q77 are located in the Na1 and Na2 binding sites and alanine 
mutants give 40% and 60% activities. The X-ray crystal structures of these mutants 
were solved at 2.9 Å and 3.2 Å respectively. Overall, both mutants form the inward 
facing conformation as seen for the WT structure. In the E260A structure, Na1 could 
not be observed in the Na1 binding site. In the Q77A structure, electron density was 
much weaker in both the Na1 and Na2 binding sites. This may due to the mutation but 
also could be due to the low resolution of the data. These results indicate that the 
protein can still take the same conformation even when the functionally important 
sodium ions are not bound.   
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Local conformational changes were observed in the Q77A structure around 
the part of the panel domain that would come from the crystal packing and explain the 
flexibility of the panel domain.  This observation supports the alternating access 
model of the secondary active transporter, in which movement between the core and 
the panel domain could happen during the transport of the substrate. 
 The X-ray crystal structures of ASBT from Yersinia frederiksenii (ASBTYf) 
were solved as the inward facing and the outward facing conformations. The two 
structures elucidated the supposed mechanism of the transport with the movement of 
the two domains that could be applied to ASBTNM and also human ASBT as well. 
Comparisons of human ASBT and bacterial ASBTs shows highly conserved Na1 and 
Na2 binding sites whereas the residues in the inward-open pocket in which the 
taurocholate binds in the ASBTNM structure are less conserved.   
 In addition to the proteoliposome assay, other biophysical techniques were 
tried to investigate the taurocholic acid and ASBTNM binding properties. CD 
spectroscopy and ITC measurement did not work well, likely due to the detergent 
aspect of taurocholic acid, which may stabilise the protein. Although the optimization 
of the experimental conditions has not been done, preliminary results with the MST 
suggest that it may be useful in measuring the binding of taurocholic acid to ASBTNM.  
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Appendix1 
Crystallisation screens: MemGold HT-96 
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2 
MemGold  HT-96  Rows A - B   MD1-41 
 
 
Tube # Salt  Buffer pH  Precipitant 
A1 
None 0.08 M sodium citrate 5.2 2.2 M ammonium sulfate 
A2 
None 0.01 M Tris 8.0 1.2 M tri-sodium citrate 
A3 
None 0.015 M tricine 8.5 24 % w/v PEG 4000 
A4 
0.36 M sodium chloride/0.1% w/v sodium 
azide 
0.015 M sodium phosphate 7.0 9.9 % w/v PEG 4000 
A5 
0.3 M sodium chloride 0.01 M Tris 8.0 27.5 % w/v PEG 4000 
A6 
None 0.225 M MES/bis-tris 6.6 6.6 % w/v PEG 6000 
A7 
0.1 M ammonium sulfate  0.1 M HEPES 7.5 12.0 % w/v PEG 4000/ 22 % v/v glycerol 
A8 
0.02 M calcium chloride/0.01 M magnesium 
sulfate/0.02 M sodium chloride 
0.02 M MES 6.5 7.7 % w/v PEG 1500 
A9 
None 0.05 M HEPES 7.5 2.5 M ammonium sulfate 
A10 
None 0.0665 M HEPES 7.5 1.1 M tri-sodium citrate 
A11 
None 0.15 M potassium phosphate 6.5 3.3 M ammonium sulfate 
A12 
0.1 M magnesium acetate 0.1 M sodium citrate 5.8 14 % w/v PEG 5000 MME 
B1 
0.1 M sodium chloride 0.02 M sodium citrate 5.6 11 % w/v PEG 3350 
B2 
0.1 M sodium chloride 0.02 M sodium citrate 5.6 5.5 % w/v PEG 3350 
B3 
0.05 M calcium chloride/0.05 M barium 
chloride 
0.1 M Tris 8.2 32 % v/v PEG 400 
B4 
0.05 M sodium chloride 0.1 M sodium phosphate 6.2 16 % w/v PEG 4000 
B5* 
0.1 M magnesium chloride 0.03 M Tris-hydrochloride 8.2 19 % w/v PEG 4000 
B6 
0.2 M sodium chloride 0.025 M HEPES 7.5 13 % w/v PEG 4000 
B7 
None 0.1 M HEPES 7.5 11 % w/v PEG 3350 
B8 
0.1 M sodium chloride 0.02 M KMES 6.7 6.6 % w/v PEG 4000 
B9 
0.1 M potassium chloride 0.02 M Tris 7.0 20 % w/v PEG 4000 
B10 
0.05 M magnesium chloride/0.1% w/v 
sodium azide 
0.1 M sodium cacodylate 6.7 6.6 % w/v PEG 3350 
B11* 
0.2 M potassium chloride 0.1 M sodium citrate 5.5 37 % v/v pentaerythritol propoxylate 
(5/4 PO/OH) 
B12 
None 0.1 M Tris 8.0 5.5 %  w/v PEG 4000 
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2 
MemGold  HT-96  Rows A - B   MD1-41 
 
 
Tube # Salt  Buffer pH  Precipitant 
A1 
None 0.08 M sodium citrate 5.2 2.2 M ammonium sulfate 
A2 
None 0.01 M Tris 8.0 1.2 M tri-sodium citrate 
A3 
None 0.015 M tricine 8.5 24 % w/v PEG 4000 
A4 
0.36 M sodium chloride/0.1% w/v sodium 
azide 
0.015 M sodium phosphate 7.0 9.9 % w/v PEG 4000 
A5 
0.3 M sodium chloride 0.01 M Tris 8.0 27.5 % w/v PEG 4000 
A6 
None 0.225 M MES/bis-tris 6.6 6.6 % w/v PEG 6000 
A7 
0.1 M ammonium sulfate  0.1 M HEPES 7.5 12.0 % w/v PEG 4000/ 22 % v/v glycerol 
A8 
0.02 M calcium chloride/0.01 M magnesium 
sulfate/0.02 M sodium chloride 
0.02 M MES 6.5 7.7 % w/v PEG 1500 
A9 
None 0.05 M HEPES 7.5 2.5 M ammonium sulfate 
A10 
None 0.0665 M HEPES 7.5 1.1 M tri-sodium citrate 
A11 
None 0.15 M potassium phosphate 6.5 3.3 M ammonium sulfate 
A12 
0.1 M magnesium acetate 0.1 M sodium citrate 5.8 14 % w/v PEG 5000 MME 
B1 
0.1 M sodium chloride 0.02 M sodium citrate 5.6 11 % w/v PEG 3350 
B2 
0.1 M sodium chloride 0.02 M sodium citrate 5.6 5.5 % w/v PEG 3350 
B3 
0.05 M calcium chloride/0.05 M barium 
chloride 
0.1 M Tris 8.2 32 % v/v PEG 400 
B4 
0.05 M sodium chloride 0.1 M sodium phosphate 6.2 16 % w/v PEG 4000 
B5* 
0.1 M magnesium chloride 0.03 M Tris-hydrochloride 8.2 19 % w/v PEG 4000 
B6 
0.2 M sodium chloride 0.025 M HEPES 7.5 13 % w/v PEG 4000 
B7 
None 0.1 M HEPES 7.5 11 % w/v PEG 3350 
B8 
0.1 M sodium chloride 0.02 M KMES 6.7 6.6 % w/v PEG 4000 
B9 
0.1 M potassium chloride 0.02 M Tris 7.0 20 % w/v PEG 4000 
B10 
0.05 M magnesium chloride/0.1% w/v 
sodium azide 
0.1 M sodium cacodylate 6.7 6.6 % w/v PEG 3350 
B11* 
0.2 M potassium chloride 0.1 M sodium citrate 5.5 37 % v/v pentaerythritol propoxylate 
(5/4 PO/OH) 
B12 
None 0.1 M Tris 8.0 5.5 %  w/v PEG 4000 
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3 
 
MemGold HT-96   Rows C- D   MD1-41 
 
Tube # Salt Buffer pH  Precipitant 
C1 0.1 M sodium chloride 0.02 M Tris 7.0 7.7 % w/v PEG 4000 
C2 
0.1 M magnesium chloride 0.1 M Tris 7.5 22 % v/v PEG 400 
C3 
0.04 M sodium chloride 0.04 M Tris 8.0 27 % v/v PEG 350 MME 
C4 
0.05 M sodium chloride/0.02 M 
magnesium chloride 
0.1 M sodium citrate 6.0 22 % v/v PEG 400 
C5 
None 0.1 M sodium acetate 5.5 8.8 % w/v PEG 2000 MME 
C6 
None 0.4 M ammonium acetate 8.0 13 % w/v PEG 2000 MME 
C7 
None 0.02 M bis Tris 7.0 15 % w/v PEG 2000 
C8 
0.1 M sodium chloride/0.1 M 
magnesium chloride 
0.02 M Tris 7.5 11 % w/v PEG 1500 
C9 
0.1 M sodium chloride/0.1 M 
magnesium chloride 
0.1 M HEPES 8.0 11 % w/v PEG 1500 
C10 
0.2 M sodium acetate/0.2 M Potassium 
Chloride 
0.1 M HEPES 7.0 22 % w/v PEG 3000 
C11 
0.02 M nickel sulfate 0.01 M HEPES 7.0 33 % v/v Jeffamine-M600  
C12 
0.15 M sodium chloride 0.1 M Tris 8.0 13 % w/v PEG 6000 
D1 
0.2 M calcium chloride 0.1 M HEPES 7.5 53 % v/v PEG 400 
D2 
0.05 M magnesium acetate 0.05 M sodium acetate 5.0 28 % v/v PEG 400 
D3 
None 0.05 M HEPES 7.5 22 % v/v PEG 4000 
D4 
0.2 M calcium chloride 0.1 M Tris hydrochloride 8.0 44 % v/v PEG 400 
D5 
0.05 M magnesium acetate 0.05 M sodium acetate 5.4 24 % v/v PEG 400 
D6 
0.2 M calcium chloride 0.1 M MES 6.5 26 % v/v PEG 350 MME 
D7 
0.1 M potassium chloride 0.1 M Tris 8.5 39 % v/v PEG 400 
D8 
0.05 M magnesium chloride 0.1 M glycine 9.0 22 % v/v PEG 400 
D9 
0.1 M ammonium sulfate 0.1 M glycine 3.8 28 % w/v tri-ethylene 
glycol 
D10 
0.15 M sodium formate 0.1 M HEPES 7.2 18 % w/v PEG 3350 
D11 
None 0.2 M sodium acetate 6.8 8.8 % w/v PEG 6000 
D12 
0.2 M potassium chloride 0.1 M MES 6.5 18 % w/v PEG 6000 
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4 
 
MemGold HT-96   Rows E - F   MD1-41 
 
Tube # Salt  Buffer pH  Precipitant 
E1 0.22 M sodium citrate 0.1 M Tris 8.0 35 % v/v PEG 400 
E2 None 0.1 M sodium acetate 4.5 17 % v/v PEG 400 
E3 None 0.02 M Tris 8.5 1.0 M lithium sulfate/1.8 % 
w/v PEG 8000 
E4 None 0.02 M Tris 7.5 22 % v/v PEG 550 MME 
E5 0.05 M sodium chloride 0.02 M glycine 10.0 33 % w/v PEG 1000 
E6 0.2 M magnesium chloride 0.1 M Tris 8.5 25 % w/v PEG 4000 
E7 0.2 M magnesium chloride 0.1 M sodium cacodylate 6.5 31 % w/v PEG 2000 
E8 None 0.64 M sodium acetate 4.6 18 % w/v PEG 3350 
E9 0.1 M sodium chloride/0.1 M 
cadmium chloride 
0.1 M Tris hydrochloride 8.0 33 % v/v PEG 400 
E10 None 0.1 M Bicine 8.9 31 % w/v PEG 2000 
E11 0.05 M sodium sulfate/0.05 M 
lithium sulfate 
0.05 M Tris 8.5 35 % v/v PEG 400 
E12 0.1 M sodium chloride 0.05 M glycine 9.5 33 % v/v PEG 300 
F1 0.3 M magnesium nitrate 0.1 M Tris 8.0 23 % w/v PEG 2000 
F2 0.12 M lithium sulfate 0.02 M Tris/0.1 M sodium 
citrate 
7.5/ 5.0 20 % v/v PEG 300 
F3 0.1 M sodium chloride 0.12 M Tris 9.4 20 % v/v PEG 400 
F4 0.2 M sodium chloride 0.1 M HEPES 7.0 22 % v/v PEG 550 MME 
F5 0.1 M sodium chloride/0.325 M 
sodium acetate 
0.1 M Tris 8.0 21 % v/v PEG 400 
F6 0.02 M sodium citrate 0.08 M sodium phosphate 6.2 18 % w/v PEG 2000 
F7 0.02 M potassium nitrate 0.03 M potassium citrate 6.5 7.7 % w/v PEG 4000 
F8 0.1 M sodium chloride/0.005 M 
magnesium chloride 
0.1 M Tris 8.5 30 % w/v PEG 2000 MME 
F9 0.2 M calcium chloride 0.1 M HEPES 7.0 33 % v/v PEG 400 
F10 0.1 M calcium chloride 0.1 M Tris 6.5 13 % w/v PEG 2000 MME 
F11 0.2 M ammonium sulfate/0.02 M 
sodium chloride 
0.02 M sodium acetate 4.0 33 % v/v PEG 200 
F12 0.07 M sodium chloride 0.05 M sodium citrate 4.5 22 % v/v PEG 400 
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MemGold HT-96   Rows G - H   MD1-41 
 
Tube # Salt  Buffer pH  Precipitant 
G1 0.2 M ammonium sulfate 0.1 M sodium acetate 4.6 28 % v/v PEG 550 MME 
G2 None 0.05 M glycine 9.0 55 % v/v PEG 400 
G3 0.1 M magnesium chloride/0.1M 
sodium chloride 
0.1 M Tris 8.5 33 % v/v PEG 400 
G4 0.1 M lithium sulfate/0.05 M di-
sodium hydrogen phosphate  
0.05 M citric acid None 19 % w/v PEG 1000 
G5 0.2 M magnesium chloride/ 0.1 M 
potassium chloride 
0.025 M sodium citrate 4.0 33 % v/v PEG 400 
G6 0.05 M zinc acetate 0.05 M MES 6.1 11 % w/v PEG 8000 
G7 0.3 M magnesium nitrate 0.1 M Tris 8.0 22 % w/v PEG 8000 
G8 0.1 M sodium chloride/4% v/v 
ethylene glycol 
0.1 M MES 6.5 33 % v/v PEG 400 
G9 0.05 M sodium chloride 0.1 M sodium citrate 5.5 26 % v/v PEG 400 
G10 0.1 M lithium sulfate 0.1 M glycine 9.3 30 % v/v PEG 400 
G11* 0.15 M potassium citrate/ 0.05 M 
lithium citrate 
0.1 M sodium phosphate - 22 % w/v PEG 6000 
G12 0.001 M zinc sulphate 0.05 M HEPES 7.8 28 % v/v PEG 600 
H1 0.1 M sodium chloride 0.1 M sodium phosphate 7.0 33 % v/v PEG 300 
H2 0.1 M sodium chloride 0.05 M Bicine 9.0 33 % v/v PEG 300 
H3 0.05 M zinc acetate/6% v/v 
ethylene glycol  
0.1 M sodium cacodylate 6.0 6.6 % w/v PEG 8000 
H4 0.2 M lithium sulfate 0.1 M sodium citrate 3.5 28 % v/v PEG 400 
H5 0.1 M sodium chloride 0.1 M Tris 7.5 11 % w/v PEG 4000 
H6* 0.05 M lithium sulfate 0.1 M tricine 7.4 7 % w/v PEG 3000 
H7* 0.2 M calcium chloride 0.1 M MES 6.5 33% v/v PEG 400 
H8* 1 M sodium chloride 0.1 M sodium citrate 6.0 28% w/v PEG 4000 
H9* None 0.1 M HEPES 7.5 11% w/v PEG 4000 
H10* 0.002 M zinc sulfate 0.08 M HEPES 7.0 25 % v/v Jeffamine 
ED2001 
H11* 0.001 M cadmium chloride/0.03 
M magnesium chloride 
0.1 M MES 6.5 30 % v/v PEG 400 
H12* None 0.1 M bis-tris-propane 7.0 3.0 M sodium chloride 
*These conditions have been changed from the pre-release (prior to June 2007) beta version of 
MemGold.  The pre-release conditions have been moved to the sister screen, MemPlus (MD1-44), 
a new screen for Outer Membrane protein crystallization." 
 
 
Abbreviations: 
ADA; N-(2-Acetamido)iminodiacetic Acid, Bicine; N,N-Bis(2-hydroxyethyl)glycine, CHES; 2-(N-Cyclohexylamino)ethane sulfonic Acid, 
HEPES; N-(2-hydroxyethyl)-piperazine-N'-2-ethanesulfonic acid, KMES; 2-(N-morpholino)ethanesulfonic acid potassium salt, MES; 2-(N-
morpholino)ethanesulfonic acid, MME; Monomethylether, PEG; Polyethylene glycol, Tricine; N-[Tris(hydroxymethyl)methyl]glycine, Tris; 
2-Amino-2-(hydroxymethyl)propane-1,3-diol, Tris HCl; 2-Amino-2-(hydroxymethyl)propane-1,3-diol, hydrochloride.] 
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Crystallisation screens: MemSys & MemStart HT-96 
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4 
MemStart™ & MemSys™ HT-96 Rows A - D  MD1-33 
 
Tube # Salt Buffer pH Precipitant 
A1 None 0.1 M sodium acetate 4.6 2 M ammonium sulfate 
A2 None 0.1 M ADA 6.5 1 M ammonium sulfate 
A3 None None - 2 M ammonium sulfate 
A4 None 0.1 M Tris 8.5 2 M ammonium sulfate 
A5 None 0.1 M Na HEPES 7.5 1.5 M lithium sulfate 
A6 None 0.1 M sodium acetate 4.6 1 M magnesium sulfate 
A7 None 0.1 M tri-sodium citrate 5.6 1 M magnesium sulfate 
A8 0.1 M lithium sulfate 0.1 M ADA 6.5 1 M magnesium sulfate 
A9 None 0.1 M ammonium dihydrogen phosphate 6.5 None 
A10 0.1 M ammonium sulfate 0.5 M di-potassium hydrogen 
phosphate/ 0.5 M di-sodium hydrogen 
phosphate 
7.5 None 
A11 0.1M lithium sulfate 0.1 M sodium acetate 4.6 1 M ammonium dihydrogen 
phosphate 
A12 None 0.1 M tri-sodium citrate 5.6 1 M ammonium dihydrogen 
phosphate 
B1 None 0.1 M Tris 8.5 2 M ammonium dihydrogen 
phosphate 
B2 None None 4.6 2 M sodium formate 
B3 None None - 4 M sodium formate 
B4 None 0.1 M MES 6.5 1.4 M sodium acetate 
B5 None 0.1 M Na HEPES 7.5 1.4 M tri-sodium citrate 
B6 None 0.1 M Na HEPES 7.5 1 M potassium sodium tartrate 
B7 None 0.1 M Na HEPES 7.5 2 % v/v PEG 400/ 2 M ammonium 
sulfate 
B8 0.1M magnesium chloride 0.1 M sodium acetate 4.6 30 % v/v PEG 400 
B9 0.1M sodium chloride 0.1 M tri-sodium citrate 5.6 30 % v/v PEG 400 
B10 0.1M lithium sulfate 0.1 M tri-sodium citrate 5.6 30 % v/v PEG 400 
B11 0.3 M lithium sulfate 0.1 M ADA 6.5 30 % v/v PEG 400 
B12 0.1 M magnesium chloride 0.1 M Na HEPES 7.5 30 % v/v PEG 400 
C1 0.1 M ammonium sulfate 0.1 M Na HEPES 7.5 30 % v/v PEG 400 
C2 0.2 M tri-sodium citrate 0.1 M Tris 8.5 30 % v/v PEG 400 
C3 0.1 M zinc acetate 0.1 M sodium acetate 4.6 12 % w/v PEG 4K 
C4 0.2 M ammonium sulfate 0.1 M sodium acetate 4.6 12 % w/v PEG 4K 
C5 None 0.1 M sodium acetate 4.6 12 % w/v PEG 4K 
C6 0.1 M lithium sulfate 0.1 M tri-sodium citrate 5.6 12 % w/v PEG 4K 
C7 0.1 M sodium chloride 0.1 M tri-sodium citrate 5.6 12 % w/v PEG 4K 
C8 0.1 M lithium sulfate 0.1 M ADA 6.5 12 % w/v PEG 4K 
C9 0.1 M sodium chloride 0.1 M Na HEPES 7.5 12 % w/v PEG 4K 
C10 0.1 M ammonium sulfate 0.1 M Na HEPES 7.5 12 % w/v PEG 4K 
C11 0.2 M magnesium chloride 0.1 M Tris 8.5 12 % w/v PEG 4K 
C12 0.2 M lithium sulfate hydrate 0.1 M Tris 8.5 12 % w/v PEG 4K 
D1 0.2 M ammonium sulfate None - 12 % w/v PEG 4K 
D2 0.1 M sodium chloride 0.1 M sodium acetate 4.6 12 % w/v PEG 6K 
D3 0.1 M magnesium chloride 0.1 M sodium acetate 4.6 12 % w/v PEG 6K 
D4 0.1 M magnesium chloride 0.1 M ADA 6.5 12 % w/v PEG 6K 
D5 0.1 M di-ammonium hydrogen phosphate 0.1 M Tris 8.5 12 % w/v PEG 6K 
D6 1 M lithium sulfate None - 2 % w/v PEG 8K 
D7 0.2 M sodium acetate 0.1 M MES 6.5 10 % w/v PEG 8K 
D8 0.2 M zinc acetate 0.1 M MES 6.5 10 % w/v PEG 8K 
D9 0.2 M calcium acetate 0.1 M MES 6.5 10 % w/v PEG 8K 
D10 None 0.1 M Tris 8.5 10 % w/v PEG 8K 
D11 0.2 M ammonium sulfate None - 10 % w/v PEG 8K 
D12 0.5 M lithium sulfate None - 10 % w/v PEG 8K 
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5 
MemStart™ & MemSys™ HT-96 Rows E- H   MD1-33 
 
Abbreviations: 
Tube # Salt 1 Salt 2 Buffer pH Precipitant 
E1 None None 0.1 M Na citrate 5.5 2.5 M ammonium sulfate 
E2 0.1 M sodium chloride 0.1 M lithium sulfate 0.1 M Na citrate 3.5 30 % v/v PEG 400 
E3 0.1 M sodium chloride 0.1 M magnesium chloride 0.1 M Na citrate 4.5 30 % v/v PEG 400 
E4 0.1 M sodium chloride None 0.1 M Na citrate  5.5 30 % v/v PEG 400 
E5 0.1 M sodium chloride 0.1 M lithium sulfate 0.1 M Na citrate 5.5 30 % v/v PEG 400 
E6 0.1 M sodium chloride 0.1 M magnesium chloride 0.1 M Na citrate 5.5 30 % v/v PEG 400 
E7 None None 0.1 M MES 6.5 2.5 M ammonium sulfate 
E8 None None 0.1 M MES 6.5 30 % v/v PEG 400 
E9 0.1 M sodium chloride None 0.1 M MES 6.5 30 % v/v PEG 400 
E10 0.1 M sodium chloride 0.1 M lithium sulfate 0.1 M MES 6.5 30 % v/v PEG 400 
E11 0.1 M sodium chloride 0.1 M magnesium chloride 0.1 M MES 6.5 30 % v/v PEG 400 
E12 None None 0.1 M MOPS 7.0 30 % v/v PEG 400 
F1 None None 0.1 M Na HEPES 7.5 2.5 M ammonium sulfate 
F2 0.1 M sodium chloride None 0.1 M MOPS 7.0 30 % v/v PEG 400 
F3 None None 0.1 M Na HEPES 7.5 30 % v/v PEG 400 
F4 0.1 M sodium chloride None 0.1 M Na HEPES 7.5 30 % v/v PEG 400 
F5 0.1 M sodium chloride 0.1 M lithium sulfate 0.1 M Na HEPES 7.5 30 % v/v PEG 400 
F6 0.1 M sodium chloride 0.1 M magnesium chloride 0.1 M Na HEPES 7.5 30 % v/v PEG 400 
F7 None None 0.1 M Tris 8.5 1.5 M lithium sulfate 
F8 0.1 M sodium chloride None 0.1 M Tris 8.5 30 % v/v PEG 400 
F9 0.1 M sodium chloride 0.1 M lithium sulfate 0.1 M Tris 8.5 30 % v/v PEG 400 
F10 0.1 M sodium chloride 0.1 M magnesium chloride 0.1 M Tris 8.5 30 % v/v PEG 400 
F11 0.1 M sodium chloride 0.1 M lithium sulfate 0.1 M CAPSO 9.5 30 % v/v PEG 400 
F12 0.1 M sodium chloride 0.1 M magnesium chloride 0.1 M CAPSO 9.5 30 % v/v PEG 400 
G1 None None 0.1 M Na citrate 5.5 1.5 M sodium phosphate 
G2 0.1 M sodium chloride 0.1 M magnesium chloride 0.1 M Na citrate  3.5 12 % w/v PEG 4K 
G3 0.1 M sodium chloride 0.1 M lithium sulfate 0.1 M Na citrate 4.5 12 % w/v PEG 4K 
G4 0.1 M sodium chloride None 0.1 M Na citrate 5.5 12 % w/v PEG 4K 
G5 0.1 M sodium chloride 0.1 M lithium sulfate 0.1 M Na citrate 5.5 12 % w/v PEG 4K 
G6 0.1 M sodium chloride 0.1 M magnesium chloride 0.1 M Na citrate 5.5 12 % w/v PEG 4K 
G7 None None 0.1 M MES 6.5 1.5 M sodium phosphate 
G8 None None 0.1 M MES 6.5 12 % w/v PEG 4K 
G9 0.1 M sodium chloride None 0.1 M MES 6.5 12 % w/v PEG 4K 
G10 0.1 M sodium chloride 0.1 M lithium sulfate 0.1 M MES 6.5 12 % w/v PEG 4K 
G11 0.1 M sodium chloride 0.1 M magnesium chloride 0.1 M MES 6.5 12 % w/v PEG 4K 
G12 None None 0.1 M MOPS 7.0 12 % w/v PEG 4K 
H1 None None 0.1 M Na HEPES 7.5 1.5 M potassium phosphate 
H2 0.1 M sodium chloride None 0.1 M MOPS 7.0 12 % w/v PEG 4K 
H3 None None 0.1 M Na HEPES 7.5 12 % w/v PEG 4K 
H4 0.1 M sodium chloride None 0.1 M Na HEPES 7.5 12 % w/v PEG 4K 
H5 0.1 M sodium chloride 0.1 M lithium sulfate 0.1 M Na HEPES 7.5 12 % w/v PEG 4K 
H6 0.1 M sodium chloride 0.1 M magnesium chloride 0.1 M Na HEPES  7.5 12 % w/v PEG 4K 
H7 None None 0.1 M Tris  8.5 1.5  M potassium phosphate 
H8 0.1 M sodium chloride None 0.1 M Tris  8.5 12 % w/v PEG 4K 
H9 0.1 M sodium chloride 0.1 M lithium sulfate 0.1 M Tris  8.5 12 % w/v PEG 4K 
H10 0.1 M sodium chloride 0.1 M magnesium chloride 0.1 M Tris  8.5 12 % w/v PEG 4K 
H11 0.1 M sodium chloride 0.1 M lithium sulfate 0.1 M CAPSO  9.5 12 % w/v PEG 4K 
H12 0.1 M sodium chloride 0.1 M magnesium chloride 0.1 M CAPSO  9.5 12 % w/v PEG 4K
ADA; N-(2-Acetamido)iminodiacetic Acid, CAPSO; 3-(Cyclohexylamino)-2-hydroxy-1-propanesulfonic Acid Sodium Salt, Na HEPES; N-
(2-hydroxyethyl)-piperazine-N'-2-ethanesulfonic acid, sodium salt MES; 2-(N-morpholino) ethanesulfonic acid, MME; Monomethylether, 
MOPS; 3-(N-Morpholino)-propanesulfonic acid, PEG; Polyethylene glycol (4K corresponds to the molecular weight, in thousands 
of Daltons, of PEG,) Tris; 2-Amino-2-(hydroxymethyl) propane-1,3-diol. 
 
Note: The pH of each final reagent is checked and adjusted back to the stated pH of the buffer (±0.2 pH units) as appropriate. 
 
Manufacturer’s datasheets are available on request 
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Appendix2 
ASBTNM DNA sequence; 948 bps 
ATGAATATCCTCAGTAAAATCAGCAGCTTTATCGGAAAAACATTTTCCCTC
TGGGCCGCGCTCTTTGCCGCCGCCGCTTTTTTCGCGCCCGACACCTTCAAA
TGGGCGGGGCCTTATATTCCTTGGCTGTTGGGCATTATTATGTTCGGTATG
GGTTTGACGCTCAAACCTTCCGACTTCGATATTTTGTTCAAACATCCCAAA
GTCGTCATCATCGGCGTAATCGCACAATTCGCCATTATGCCGGCAACCGC
CTGGCTGCTGTCCAAACTGTTGAACCTGCCTGCCGAAATCGCGGTCGGCG
TGATTTTGGTCGGCTGCTGCCCGGGCGGTACGGCTTCCAATGTGATGACCT
ATCTGGCGCGTGGCAATGTGGCTTTGTCGGTTGCCGTTACGTCTGTTTCCA
CCCTGATTTCCCCATTGCTGACTCCCGCCATCTTCCTGATGCTTGCCGGCG
AAATGCTGGAAATCCAAGCGGCCGGTATGTTGATGTCCATCGTCAAAATG
GTTTTGCTCCCCATTGTTTTGGGTTTGATTGTCCATAAGGTTTTGGGCAGTA
AAACCGAAAAGCTGACCGATGCGCTGCCGCTGGTTTCCGTTGCCGCCATC
GTGCTGATTATCGGCGCGGTTGTTGGGGCAAGCAAAGGCAAGATTATGGA
AAGCGGCCTGCTGATTTTTGCGGTTGTCGTACTCCACAACGGCATCGGCTA
CCTGCTCGGCTTCTTTGCCGCCAAATGGACCGGCCTGCCTTATGATGCACA
AAAAACGCTGACCATCGAAGTCGGTATGCAAAACTCGGGCCTGGCCGCCG
CGCTTGCCGCCGCACACTTTGCCGCCGCGCCGGTCGTTGCCGTTCCGGGCG
CATTGTTCAGCGTGTGGCACAATATCTCCGGCTCGCTGCTGGCAACTTATT
GGGCGGCCAAAGCCGGTAAACATAAAAAACCCTAA 
 
 
	 
